Peptide Pools for Infectious Diseases Research

JPT's Peptide Pools for Infectious Diseases Research

PepMix™ Peptide Pools are crucial tools for studying immune responses to infectious diseases, including viral and bacterial infections. JPT’s PepMix™ products enable researchers to assess T cell reactivity, improve vaccine formulations, and explore immune protection mechanisms. Below, you will find key studies referencing JPT’s PepMix™ Peptide Pools in various research.

References with PepMix™ Peptide Pools - Infectious Diseases

2026

Early Combination Antiretroviral Therapy Initiation During Primary HIV Infection Restricts HIV Reservoirs and Gut-Driven Inflammation but Fails to Rewire the Systemic Cytokine LandscapeBono et al., Open Forum Infectious Diseases (2026) - PMID: 41846601Product used: PepMix™ HIV (GAG) Ultra

Smallpox-specific T cells in vaccinated centenarians exhibit different phenotypic and metabolic traits of long-term memory compared to SARS-CoV-2-specific memory T cells.De Biasi et al., Research Square (2026) Product used: PepMix™ Vaccinia virus (MVA121L), PepMix™ Vaccinia virus (MVA074R), PepMix™ Vaccinia virus (MVA105L)

Lipid Self-Assembling Nanoparticles As a Novel Platform for mRNA-based VaccinationDe Chiara et al., Molecular Therapy Nucleic Acids (2026)Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)

Ancestral Wuhan SARS-CoV-2 anti-spike CD4+ T cells predict protection from symptomatic omicron breakthrough infectionDurier et al., Vaccine (2026) Product used: PepMix™ SARS-CoV-2 (Spike B.1.1.529 / BA.1 / Omicron), PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1)

Immune responses following sequential mRNA booster doses targeting the SARS-CoV-2 omicron variants in immunocompromised individuals – A 3.5-year follow-upEkstrom et al., Vaccine (2026) - PMID: 41740459Products used: PepMix™ SARS-CoV-2 (Spike EG.5.1), PepMix™ SARS-CoV-2 (Spike JN.1), PepMix™ SARS-CoV-2 (Spike XBB.1.5), PepMix™ SARS-CoV-2 (Spike B.1.1.529 / BA.4 & BA.5 / Omicron), PepMix™ SARS-CoV-2 (Spike Glycoprotein)

Chronic Kidney Disease-Associated Defect in Humoral Immune Response Is Driven by InflammationEspi et al., Toxins (2026) - PMID: 41745770Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)

Loss of systemic anti-viral immunity and LMP1-driven suppressive myeloid tumour niches converge to shape the immunobiology of EBV+ 3 diffuse large B-cell lymphomaFennell et al., BioRxiv (2026) Product used: PepMix™ EBV (LMP1)

COVID-19 boosters restore virus-specific immune responses in kidney transplant recipients unresponsive to primary vaccinationDen Hartog et al., NPJ Viruses Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1), PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB2)

Long-Term Immunity and IgG Subclass Response Following Hepatitis E Vaccination: A Longitudinal Cohort Study in Matlab, BangladeshHaque et al., International Journal of Infectious Disease (2026) - PMID: 41763639Product used: PepMix™ HEV (ORF2)

Immunological dysfunction associated with SARS-CoV-2 persistence in immunocompromised patientsJohannsen et al., Clinical and Experimental Immunology (2026)Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein), Custom PepMix

CD4+ T cell-mediated immunity protects from VSV-SUD lethal challenge in a mouse model of Sudan virus infectionKelchtermans et al., Nature Immunology (2026)Product used: PepMix™ Sudan Ebolavirus (GP/Uganda-00)

An Ad26-MVA-BN-based therapeutic vaccine targeting HPV16 and HPV18 related disease is immunogenic in preclinical models and in women with persistent HPV infectionsKhan et al., Clinical and Translational Immunology (2026) Product used: PepMix™ HPV16 (E2), PepMix™ HPV 16 (E6), PepMix™ HPV 16 (E7), PepMix™ HPV18 (E2), PepMix™ HPV 18 (E6), PepMix™ HPV 18 (E7)

Vector-directed immunity and boosting capacity of VRP-srRNA anti-tumor vaccinesMa et al., NPJ Vaccines (2026) Product used: PepMix™ VEEV (Spike Glycoprotein E2), PepMix™ Human (CEA), OVA (257-264) Chicken Ovalbumin Peptide - SIINFEKL, PepMix™ HIV-1 (GAG) Ultra

Long-term HIV-1 remission achieved through allogeneic haematopoietic stem cell transplant from a CCR5Δ32/Δ32 sibling donorMyhre et al., Nature Microbiology (2026)Product used: PepMix™ HIV-1 (GAG) Ultra, PepMix™ HIV-1 (NEF) Ultra, PepMix™ HIV-1 (POL) Ultra, CEF Pool (extended)

Design and immunogenicity evaluation of panrecombinant vaccines based on the consensus sequence of severe acute respiratory syndrome coronavirus-2 spike proteinNa et al., Scientific Reports (2026) Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)

Role of BK Virus CTLs in the Treatment of BK Virus–Associated Nephropathy in Kidney-Transplant and Hematopoietic Cell Transplant RecipientsOlson et al., Transplant Infectious Disease (2026) Products used: PepMix™ BKV (small T antigen), PepMix™ BKV (large T antigen), PepMix™ BKV (capsid protein VP1), PepMix™ BKV (capsid protein VP2), PepMix™ BKV (capsid protein VP2, isoform VP3)

Heterologous vs. homologous vaccine regimens: Sulfated lactosyl archaeol (SLA) archaeosome-adjuvanted SARS-CoV-2 spike protein boost following an mRNA/LNP prime induces robust and balanced immune responses Renner et al., Vaccine (2026) - PMID: 41505874 Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)

Determinants of long-term SARS-CoV-2 immune responses in asymptomatic-to-moderate COVID-19 patients in sub-Saharan Africa Rioja et al., BMC Medicine (2026) - PMID: 41535904 Product used: PepMix™ Pan-SARS-CoV-2 Select

Long-lasting cross-reactive and polyfunctional SARS-CoV-2 T cell responses in seniors are maintained after repeated vaccination and infectionsRobertson et al., Vaccine (2026) Product used: PepMix™ SARS-CoV-2 (Spike XBB.1.5), PepMix™ SARS-CoV-2 (Spike B.1.1.529 / BA.1 / Omicron), PepMix™ SARS-CoV-2 (Spike BA.2.86)

Diminished EBV-Specific Humoral Immunity is Associated with Neuropsychiatric Long COVID Development up to 12 Months Post-COVID-19 Symptom OnsetSamaan et al., BioRxiv (2026)Products used: PepMix™ EBV (EBNA1), PepMix™ SARS-CoV-2 (NCAP), PepMix™ SARS-CoV-2 (Spike Glycoprotein), PepMix™ EBV (BZLF1)

Structure-based design of soluble prefusion-stabilized herpes simplex virus type 2 glycoprotein B antigensSponholtz et al., BioRxiv (2026) Product used: PepMix™ HSV2 (gB)

Comparison of two IGRA assays exploring cell-mediated immunity against CMV, BKV, and EBV in kidney transplant patientsTruffot et al., Microbiology Spectrum (2026) Product used: PepMix™ Human CMV (pp65), PepMix™ Human CMV (IE-1)

Antigenic-Specificity and Cytokine Profile of the T-Cell Response to Human Cytomegalovirus in Transplant RecipientsZavaglio et al., Pathogens (2026) Product used: PepMix™ Human CMV (IE-1)

2025

Functional T cell response to COVID-19 vaccination with or without natural infection with SARS-CoV-2 in adults and childrenAhtar et al., Scientific Reports (2025) - PMID: 40247005Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)

OC18 Assessment of the specific cellular immune response to the recombinant herpes zoster vaccine in people living with HIV Alessio et al., Sex Trans Infect (2025)Product used: PepMix™ HIV-1 (POL) Ultra

Comprehensive Immune and Transcriptomic Characterization of Human Cytomegalovirus Infection in Solid Organ Transplant RecipientsAmidpour, Dissertation (2025) Products used: PepMix™ Collection Human CMV (25ug/peptide)

CD4 and CD8 T-cell response is dominated by IL-10–secreting cells in children with uncomplicated Plasmodium falciparum malariaAriera et al., Immunohorizons (2025) - PMID: 41285032Products used: PepMix™ EBV (BZLF1), PepMix™ EBV (EBNA1)

Lentiviral vector-based T-cell vaccines against Zika and yellow fever viruses Authié et al., Vaccine (2025) - PMID: 40753671 Product used: PepMix™ ZIKV (NS1) Ultra

Neutralizing Antibodies Against the Porcine Endogenous Retroviruses (PERVs)Ban et al., Viruses (2025) - PMID: 41305460Product used: Custom PepMix

Prophylactic infusion of donor derived CMV specific T cells for the prevention of CMV reactivation following allogeneic HSCTBarkhordar et al., Scientific Reports (2025) Products used: PepMix™ Human CMV (IE-1), PepMix™ Human CMV (pp65)

Endemic coronavirus infection is associated with SARS-CoV-2 Fc receptor-binding antibodiesBean et al., Journal of Virology (2025) - PMID: 40387363Products used: PepMix™ SARS-CoV-2 (Nsp12) and PepMix™ SARS-CoV-2 (Nsp13)

P174 Multi-cytokine assessment of T-cell responses to varicella zoster virus glycoprotein E after vaccination with a recombinant adjuvanted subunit vaccine in patients with multiple sclerosis on immune modulating treatmentsBenedetti et al., Sex Trans Inect (2025) Product used: PepMix™ VZV (gE)

Adaptive immune responses to SARSCoV-2 in DMARD-treated patients with chronic inflammatory rheumatismsBeretta et al., Rheumatic and Muscosceletal Diseases (2025) - PMID: 40617588Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein), EF Pool

Adjuvant-Driven Modulation of Epitope Recognition and Protective Immunity in Bm86 vaccinated Holstein-Friesian cattleBishop et al., International Journal of Parasitology (2025) Product used: Custom PepMix

Influenza vaccination post-COVID-19 expands vaccine-specific effector CD4 T-cells and Tregs under positive influence of host trained innate immunity Bindhu et al., NPJ Vaccines (2025) - PMID: 41453905 Products used: PepMix™ HCoV-HKU1 (Spike Glycoprotein), PepMix™ Influenza B (HA/H0N0/Phuket/2013), PepMix™ Influenza A (NP/AnnArbor (H2N2), PepMix™ Influenza B (HA/H0N0/Austria/2021), PepMix™ Influenza A (HA/H3N2/Darwin/2021), PepMix™ Influenza A (HA/H1N1/Victoria/2019)

Humoral and cellular immunogenicity of sequential heterogeneous bivalent SARS-CoV-2 vaccinations in long-term care and retirement home residentsBreznik et al., Vaccine (2025) - PMID: 41478237Product used: PepMix™ SARS-CoV-2 (Spike B.1.1.529 / BA.1 / Omicron), PepMix™ SARS-CoV-2 (Spike B.1.1.529 / BA.4 & BA.5 / Omicron), PepMix™ SARS-CoV-2 (Spike XBB.1.5)

Development of bivalent RBD adapted COVID-19 vaccines for broad sarbecovirus immunityBruno et al., NPJ Vaccines (2025) - PMID: 40442110Products used: PepMix™ SARS-CoV-2 (S-RBD JN.1), PepMix™ SARS-CoV-2 (S-RBD B.1.1.529 / BA.4 & BA.5 / Omicron)

Immune profiling in solid organ transplant recipients with HHV-8 infection: Identification of immunological biomarkers for KICS and Kaposi’s sarcomaBusà et al., Clinical Immunology (2025) - PMID: 40651737Products used: Custom PepMix (HHV-8) & CEFX Ultra SuperStim Pool

H1N1 challenge results in rapid recall of stem-specific immunity in HA stem nanoparticle–vaccinated newborn monkeysCrofts et al., JCI Insight (2025) Product used: PepMix™ Influenza A (HA /California (H1N1))

AS01-adjuvanted vaccine alters baseline correlates of T cell response to varicella zoster virus in older adultsChan et al., Vaccine (2025) - PMID: 40592255Product used: PepMix™ VZV (gE)

CMV resistant to ganciclovir and maribavir in a heart-transplanted Patient: A case reportChinello et al., Heliyon (2025) Products used: PepMix™ Human CMV (pp65), PepMix™ Human CMV (IE-2), PepMix™ Human CMV (IE-1)

P119 Varicella zoster virus vaccination in patients with haematological diseases and primary immunodeficiencies. Assessment of specific T and B-cell responsesCoppola et al, Sec Trans Infect (2025) Product used: PepMix™ VZV (gE)

A 3-week pause versus continued Bruton tyrosine kinase inhibitor use during COVID-19 vaccination in individuals with chronic lymphocytic leukaemia (IMPROVE trial): a randomised, open-label, superiority trialCook et al., The Lancet (2025) Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein), PepMix™ SARS-CoV-2 (Spike XBB.1.5)

Rational design of ionizable lipids for intramuscular messenger ribonucleic acid vaccinesCouture-Senécal, Dissertation (2025)

Immunological memory in infected & exposure näive individuals one year post SARS-CoV-2 vaccinationDas et al., Indian Journal of Medical Research (2025) - PMID: 40347503Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)

In-depth characterization of the Immune response upon COVID-19vaccination in cancer patients Debie, Dissertation (2025) Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)

CD55 upregulation in T cells of COVID-19 patients suppresses type-I interferon responsesDetsika et al., Communications Biology (2025) - PMID: 40316776Products used: PepMix™ SARS-CoV-2 (Spike XBB.1.5), PepMix™ SARS-CoV-2 (NCAP B1.1.529 / BA.1 / Omicron)

Early de novo T cell expansion following SARS-CoV-2 infection predicts favourable clinical and virological outcomesFenn et al., EBioMedicine (2025) - PMID: 40472803Products used: PepMix™ SARS-CoV-2 (NCAP), PepMix™ SARS-CoV-2 (VME1), PepMix™ SARS-CoV-2 (Spike Glycoprotein)

De Novo Immune Induction After COVID-19 Vaccination Under B-Cell Depletion Is Characterized by Robust T-Cellular Immunity in Patients With Inflammatory Central Nervous System DiseaseFousse et al., Brain and Behavior (2025) - PMID: 40898724Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)

Longitudinal analysis of immune responses to SARS-CoV-2 recombinant vaccine S-268019-b in phase 1/2 prime-boost studyFujitani et al., Frontiers in Immunology (2025) - PMID: 40109335Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)

Sustained HIV-1 remission after heterozygous CCR5Δ32 stem cell transplantation Gaebler et al., Nature (2025)Products used: PepMix™ HIV-1 (POL) Ultra, PepMix™ HIV-1 (NEF) Ultra, PepMix™ HIV-1 (GAG) Ultra, PepMix™ HIV-1 (ENV) Ultra, PepMix™ HHV6 (U90)

Enabling global access to potent subunit vaccines with a simple and scalable injectable hydrogel platformGanesh et al., Biomaterials Science (2025) Products used: PepMix™ Influenza A (HA/Indonesia (H5N1)), PepMix™ SARS-CoV-2 (Spike Glycoprotein)

A novel vaccine platform for Lassa virusGarcía et al., Dissertation (2025) Product used: PepMix™ Lassa virus (Pre-glycoprotein complex)

Identification of soluble biomarkers that associate with distinct manifestations of long COVIDGao et al., Nature Immunology (2025) - PMID: Products used: PepMix™ EBV (BARF1), PepMix™ EBV (BMLF1), PepMix™ EBV (BRLF1), PepMix™ EBV (BZLF1), PepMix™ EBV (EBNA1), PepMix™ EBV (EBNA2), PepMix™ EBV (EBNA3a), PepMix™ EBV (EBNA3b), PepMix™ EBV (EBNA3c), PepMix™ EBV (LMP2), PepMix™ Human CMV (IE-1), PepMix™ Human CMV (IE-2), PepMix™ Human CMV (pp65)

HA-ppy immunity: unveiling the power of hyaluronan as an adjuvant in SARS-CoV-2 vaccinationGenova, Dissertation (2025) Product used: PepMix™ SARS-CoV-2 (S-RBD)

Immune profiling after SARS-CoV-2 infection: Investigation of T cell reactivity in convalescent individuals and persistent immune abnormalities in post-COVID Patients Gilberg, Dissertation (2025)Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)

ImmunoStruct enables multimodal deep learning for immunogenicity predictionGivechian et al., Nature Machine Intelligence (2025) Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)

Lung transplantation in times of Covid-19 – Immune response and clinical management of recent lung allograft recipients infected with SARS-CoV 2Glück et al., Dissertation (2025)

TGFβ links EBV to multisystem inflammatory syndrome in childrenGoetzke et al., Nature (2025) Product used: PepMix™ HSV2 (gD)

Long-term mitochondrial and metabolic impairment in lymphocytes of subjects who recovered after severe COVID-19Gómez‑Delgado et al., Cell Biology and Toxicology (2025) - PMID: 39792183Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)

COVID-19 and SARS-CoV-2 vaccination related T cell immune response in diverse populationsGupta, Dissertation (2025) Product used: PepMix™ SARS-CoV-2 (NCAP)

Celluloepidemiology—A paradigm for quantifyinginfectious disease dynamics on a population levelHa et al., Science Advances (2025) - PMID: 40378227Product used: Custom PepMix

Safety and immunogenicity of adjuvanted respiratory syncytial virus vaccine in highrisk transplant recipients: An Interventional Cohort StudyHall et al., Clinical Microbiology and Infection (2025) - PMID: 41016596Products used: PepMix™ HRSVA (Fusion Glycoprotein F0)

Immune Response after COVID-19 Vaccination in Elite Athletes Halmans, Dissertation (2025) Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)

RSV Prefusion F3 Vaccine in Lung Transplant Recipients elicits CD4+ T-cell response in all VaccineesHavlin et al., American Journal of Transplantation (2025) - PMID: 40169094Product used: PepMix™ HRSVB (Fusion Glycoprotein F0)

Cardiotropic AAV gene therapy for heart failure: a phase 1 trialHenry et al., Nature Medicine (2025) Products used: PepMix™ AAV2 (Capsid Protein VP1) & Custom Peptide Pool

Phenotypic and epigenetic profiles of circulating NK cells in spontaneous HIV-1 controllersHuber et al., eBioMedicine (2025) - PMID: 41027310Products used: PepMix™ HIV-1 (ENV) Ultra, PepMix™ Human CMV (pp65)

CD27 agonism enhances long-lived CD4 T cell vaccine responses critical for antitumor immunity Hwang et al., Science Immunology (2025) - PMID: 41417923 Products used: PepMix™ Human (ErbB2_ECD), PepMix™ Human (ErbB2_ICD), PepMix™ HIV-1 (GAG) Ultra, Custom pepMix LacZ

Prolonged effects of adenoviral vector priming on T-cell cytokine production in heterologous adenoviral vector/mRNA COVID-19 vaccination regimensIsogawa et al., Scientific Reports (2025) Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)

A vaccine targeting lung resident-memory CD4+ T cell phenotype protects against Mycobacterium tuberculosis in miceKo et al., NPJ Vaccines (2025) - PMID: 40695843Products used: PepMix™ M. tuberculosis (CFP-10), PepMix™ M. tuberculosis (ESAT-6)

Assessment of cellular and humoral immunity against varicella-zoster virus in adult allogeneic hematopoietic cell transplant recipients: a cross-sectional study assessing cellular immunity after administration of an adjuvanted recombinant zoster vaccineKonumaa et al., Journal of Infection and Chemotherapy (2025) - PMID: 41205809Products used: PepMix™ VZV (gE)

UCPVax, a CD4 helper peptide vaccine, induces polyfunctional Th1 cells, antibody response, and epitope spreading to improve antitumor immunityLaheurte et al., Cell Reports Medicine (2025) - PMID: 40543509Products used: PepMix™ Human (NY-ESO-1), PepMix™ HIV-1 (ENV) Ultra

Coordinated early immune response in the lungs is required for effective control of SARS-CoV-2 replicationLenart et al., Nature Communications (2025) - PMID: 40562777Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)

RBD-depleted SARS-CoV-2 spike generates protective immunity in cynomolgus macaquesLetscher et al., NPJ Vaccines (2025) Product used: Custom PepMix

CD24-Fc resolves inflammation and enhances anti-HIV CD8 T cells with polyfunctionality during HIV-1 infection under ARTLi et al., PLOS Pathogens (2025) - PMID: 40779581Product used: PepMix™ HIV-1 (GAG) Ultra

Depletion of plasmacytoid dendritic cells rescues HIV-reactive stem-like CD8+ T cells during chronic HIV-1 infectionLi et al., Science Translational Medicine (2025) Products used: PepMix™ HIV-1 (GAG) Ultra, PepMix™ HIV-1 (Con B gag motif)

Influenza A(H5N8) vaccine induces humoral and cell-mediated immunity against highly pathogenic avian influenza clade 2.3.4.4b A(H5N1) viruses in at-risk individualsLiedes et al., Nature Microbiology (2025) - PMID: 41350922Products used: PepMix™ SARS-CoV-2 (Spike JN.1), PepMix™ SARS-CoV-2 (Spike XBB.1.5), PepMix™ Influenza A (HA/H5N8/Astrakhan/2020), Custom PepMix™

A bivalent COVID-19 mRNA vaccine elicited broad immune responses and protection against Omicron subvariants infectionLiu et al., NPJ Vaccines (2025) - PMID: 39788981Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein), PepMix™ SARS-CoV-2 (Spike B.1.1.529 / BA.4 & BA.5 / Omicron), PepMix™ SARS-CoV-2 (Spike XBB.1.5), PepMix™ SARS-CoV-2 (Spike JN.1)

Safety and immunogenicity of an optimized self-replicating RNA platform for low dose or single dose vaccine applications: a randomized, open label Phase I study in healthy volunteersMaine et al., Nature Communications (2025) Product used: PepMix™ Influenza A (HA /California (H1N1)), PepMix™ Influenza A (HA/Indonesia (H5N1))

Characterization of neutralizing versus binding antibody and T cell responses to varicella-zoster virus in the elderlyMangmee et al., Scientific Reports (2025) Product used: PepMix™ VZV (gE)

Viral clearance and escape during therapy of COVID-19 outpatients: a prospective cohort study Martin-Blondel et al., iScience (2025) Products used: PepMix™ SARS-CoV-2 (Spike B.1.1.529 / BA.1 / Omicron), PepMix™ SARS-CoV-2 (NCAP)

Generation of an inflammatory niche in a hydrogel depot through recruitment of key immune cells improves efficacy of mRNA vaccines Meany et al., Science Advances (2025) - PMID: 40215318 Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)

Dosing interval is a major factor determining the quality of T cells induced by SARS-CoV-2 mRNA and adenoviral vector vaccinesMurray et al., Science Immunology (2025) - PMID: 40880518Products used: CEFT MHC-II Pool, PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)

Pan-recombinant vaccines based on the consensus sequence of severe acute respiratory syndrome coronavirus-2 spike protein Na et al., Research Square (2025) Products used: PepMix™ SARS-CoV-2 (Spike XBB.1.5), PepMix™ SARS-CoV-2 (Spike Glycoprotein)

Vaccination against SARS-CoV-2 provides low-level crossprotection against common cold coronaviruses in mouse and non-human primate animal modelsNaghibosadat et al., Journal of Virology (2025) - PMID: 39817773Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein), PepMix™ HCoV-229E (Spike Glycoprotein)

Comparative analysis of adaptive immunity to SARS-CoV-2 in infected children and adultsNantel et al., Pediatric Research (2025) - PMID: 40836106Products used: PepMix™ SARS-CoV-2 (Spike B.1.1.7 / Alpha), PepMix™ SARS-CoV-2 (Spike B.1.351 / Beta), PepMix™ SARS-CoV-2 (Spike P.1 / Gamma), PepMix™ SARS-CoV-2 (Spike B.1.617.2 / Delta), PepMix™ HCoV-OC43 (Spike Glycoprotein), PepMix™ HCoV-HKU1 (Spike Glycoprotein)

Immune disturbances in individuals with post-COVID syndrome are not characterized by enhanced SARS-CoV-2-specific immunity Ober et al., Journal of Infectious Diseases (2025) - PMID: 40279368 Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)

Strong immunogenicity and protection against SARS-CoV-2 in hamsters induced by heterologous boost vaccination with an MVA-based COVID-19 vaccine candidateOhrnberger et al., Journal of General Virology (2025) - PMID: 41258789Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)

Cellular and Humoral Immune Profiles After Hepatitis E Vaccination and InfectionØverbø et al., Viruses (2025) Product used: PepMix™ HEV (ORF2)

Pregnancy Reduces COVID-19 Vaccine Immunity Against Novel VariantsParish et al., MedRxiv (2025)Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)

Immunogenicity and efficacy of homologous and heterologous NDV and MVA SARS-CoV-2 vaccines in mice and hamstersPérez et al., NPJ Vaccines (2025) - PMID: 41271759Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)

Quantitative and Qualitative Characteristics of Human Tissue-resident SARS-CoV-2-specific CD4+ Th CellsProß, Dissertation (2025) Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)

Zelluläres und humorales Impfansprechen sowie Verträglichkeit einer Impfung gegen das humane respiratorische Synzytial-Virus (RSV) mit Arexvy bei chronischer NierenkrankheitRadun, Dissertation (2025)Product used: PepMix™ HRSVA (Fusion Glycoprotein F0), PepMix™ Pan-RSV Select, PepMix™ HRSVB (Fusion Glycoprotein F0)

Budigalimab, an anti-PD-1 inhibitor, for people living with HIV-1: a randomized, placebo-controlled phase 1b studyRamgopal et al., Nature Medicine (2025) Product used: PepMix™ HIV-1 (GAG) Ultra

Differential shaping of T cell responses elicited by heterologous ChAd68/self-amplifying mRNA SIV vaccine in macaques in combination with αCTLA4, αPD-1, or FLT3R agonistRappaport et al., Journal of Immunology (2025) - PMID: 40073084Product used: Custom PepMix

Ultra-low level HIV p24 drives immune activation in antiretroviral therapy-treated people living with HIV Richter et al., Communications Medicine (2025) - PMID: 41331331 Product used: PepMix™ HIV-1 (GAG) Ultra

Neutralizing Antibody and T-Cell Spike Targeted Responses Following Receipt of a Monovalent Omicron JN.1-Adapted mRNA COVID-19 Vaccine in Immunosuppressed and Healthy Individuals Sánchez-Simarro et al., Journal of Medical Virology (2025) - PMID: 40545672 Products used: PepMix™ SARS-CoV-2 (Spike JN.1), PepMix™ SARS-CoV-2 (Spike Glycoprotein)

Evaluation of three novel antigens and costimulatory agents for improvement of M. Tuberculosis specific interferon gamma release assays Schwarzlose-Schwarck et al., BMC Infectious Diseases (2025) - PMID: 39920589Products used: Custom PepMix, PepMix™ M. tuberculosis (ACR), PepMix™ M. tuberculosis (ESAT-6), PepMix™ M. tuberculosis (Rv1733c), PepMix™ M. tuberculosis (CFP-10), PepMix™ M. tuberculosis (TB10.4)

Repurposing anti-viral subunit and mRNA vaccines T cell immunity for intratumoral immunotherapy against solid tumorsSethi et al., NPJ Vaccines (2025) Products used: PepMix™ VZV (gE), PepMix™ HPV 18 (L1) or PepMix™ HPV16 (L1)

Comparative analysis of cellular immune responses to four seasonal inactivated influenza vaccines in younger and older adultsSilva-Moraes et al., Journal of Immunology (2025) - PMID: 41166714Products used: PepMix™ Influenza A (HA/H1N1/Victoria/2019), PepMix™ Influenza A (HA/H3N2/Darwin/2021)

Autologous HIV-specific T cell therapy targeting conserved epitopes is welltolerated in six adults with HIV: an openlabel, single-arm phase 1 studySohai et al., Nature Communications (2025) Products used: PepMix™ Human (Actin), PepMix™ HIV-1 (NEF) Ultra, PepMix™ HIV-1 (GAG) Ultra, PepMix™ HIV-1 (POL) Ultra

Cellular and humoral immunity towards SARS-CoV-2 infection and vaccination in patients with primary antibody deficiencySteiner, Dissertation (2025) Product used: PepMix™ SARS-CoV-2 (NCAP), PepMix™ HCoV-OC43 (Spike Glycoprotein), PepMix™ HCoV-229E (Spike Glycoprotein), PepMix™ SARS-CoV-2 (Spike Glycoprotein)

High Treg and PMN-MDSC densities are a hallmark of tertiary lymphoid structures in fatal cases of cervical cancer Syding et al., Journal of Immunotherapy for Cancer (2025)Products used: PepMix™ HPV 16 (E6), PepMix™ HPV 16 (E7)

Influence of SARS-CoV-2 mRNA BNT161b2 Vaccination on Humoral and Cellular Immunity in Pediatric Stem Cell Transplant Patients Thole, Dissertation (2025)Product used: PepMix™ SARS-CoV-2 (Spike B.1.1.7 / Alpha)

Design and Synthesis of Ionizable Lipids for mRNA DeliveryTilstra, Dissertation (2025) Product used: Custom PepMix

Role of prior HPV infection and CD4 T‑cell count in modulating cellular immune responses to a three‑dose nonavalent HPV vaccine schedule in PWH receiving ART Tortellini et al., BMC Medicine (2025) - PMID: 41444940 Products used: PepMix™ HPV16 (L1), PepMix™ HPV 18 (L1)

Tailoring the adjuvanticity of lipid nanoparticles by PEG lipid ratio and phospholipid modificationsVadovics et al., Nature Nanotechnology (2025) - PMID: 40550975Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)

Innate and T-cellular immune responses to sequential vaccination with chimeric hemagglutinin split influenza virus vaccines in miceVasliev et al., Vaccine (2025) - PMID: 40876140Product used: PepMix™ Influenza A (NP/Puerto Rico/8/1934 H1N1)

Detectable SARS-CoV-2 specific immune responses in recovered unvaccinated individuals 250 days post wild type infectionWeigl et al, PLOS Ones (2025) Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2), PepMix™ SARS-CoV-2 (NCAP), PepMix™ HCoV-229E (Spike Glycoprotein), PepMix™ HCoV-OC43 (Spike Glycoprotein), PepMix™ HCoV-NL63 (Spike Glycoprotein), PepMix™ HCoV-HKU1 (Spike Glycoprotein)

Immunogenicity of RSV Fusion Protein Adsorbed to Non-Pathogenic Bacillus subtilis Spores: Implications for Mucosal Vaccine Delivery in Nonclinical Animal ModelsXiao et al., Biomedicines (2025) Product used: Custom PepMix (RSV F protein)

Pregnancy and lactation induce distinct immune responses to COVID-19 booster vaccination and SARS-CoV-2 breakthrough infectionYin et al., JCI Insight (2025) - PMID: 40693463Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)

Archive

Alphaviral genetic background of self-amplifying RNA enhances protein expression and immunogenicity against SARS-CoV-2 antigenCasmil et al., Molecular Therapy (2024) Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)

Control of BKPyV-DNAemia by a Tailored Viro-Immunologic Approach Does Not Lead to BKPyV-Nephropathy Progression and Development of Donor-Specific Antibodies in Pediatric Kidney TransplantationCioni et al., Microorganisms (2024) Product used: PepMix™ EBV (LMP2)

Comparison of a SARS-CoV-2 mRNA booster immunization containing additional antigens to a spike-based mRNA vaccine against Omicron BA.5 infection in hACE2 miceHurst et al., PLoS One (2024) - PMID: 39625929Product used: PepMix™ SARS-CoV-2 (Spike B.1.351 / Beta)

A replication-incompetent adenoviral vector encoding for HSV-2 gD2 is immunogenic and protective against HSV-2 intravaginal challenge in miceRossetti et al., PLoS One (2024) - PMID: 39739963Product used: PepMix™ HSV2 (gD)

T Cell Responses to BA.2.86 and JN.1 SARS-CoV-2 Variants in Elderly SubjectsSegato et al., Vaccines (2024) Products used: PepMix™ SARS-CoV-2 (S-RBD), PepMix™ SARS-CoV-2 (S-RBD BA.2.86)

Plant Cell Culture-Derived Saponin Adjuvant Enhances Immune Response Against a Stabilized Human Metapneumovirus Pre-Fusion Vaccine CandidateSwart et al., Vaccines (2024) Product used: Custom PepMix Peptide Pool

Deciphering long-term immune effects of HIV-1/SARS-CoV-2 co-infection: a longitudinal studyVazquez-Alejo et al., Medical Microbiology & Immunology (2024)Product used: PepMix™ HIV-1 (GAG) Ultra

Cognate antigen engagement induces HIV-1 expression in latently infected CD4+ T cells from people on long-term antiretroviral therapyMoskovljevi e al., Immunity (2024) - PMID: 39612916Product used: PepMix™ HIV-1 (Con B gag motif)

Effect of XBB.1.5-adapted booster vaccination on the imprinting of SARS-CoV-2 immunityPušnik et al., Vaccines (2024) - PMID: 39572559Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein), PepMix™ SARS-CoV-2 (Spike XBB.1.5)

Adjuvants to the S1-subunit of the SARS-CoV-2 spike protein vaccine improve antibody and T cell responses and surrogate neutralization in miceBecker et al., Scientific Reports (2024)Product used: PepMix™ SARS-CoV-2 (S-RBD)

A Robust SARS-CoV-2-specific T and B Cell Response is Associated with Early Viral Clearance in SARS-CoV-2 Infected Immunocompromised IndividualsVergouwe et al., Journal of Infectious Diseases (2024) - PMID: 38843052Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein), PepMix™ SARS-CoV-2 (NCAP)

Engineered protein subunit COVID19 vaccine is as immunogenic as nanoparticles in mouse and hamster modelsMatthew et al., Scientific Reports (2024)Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)

A randomized clinical trial of the impact of melatonin on influenza vaccine: Outcomes from the melatonin and vaccine response immunity and chronobiology study (MAVRICS)Lee et al., Human Vaccines & Immunotherapeutics (2024) Product used: Custom PepMix

Minicircle-based vaccine induces potent T-cell and antibody responses against hepatitis C virusCzarnota et al., Scientific Reports (2024) Products used: Custom PepMix

Antibodies in Infectious Diseases: HIV Biomarker Discoveries, Complement Enhanced SARS-CoV-2 Neutralization and Vaccine GenerationBudylowski, Dissertation (2024)Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)

TianTan vaccinia virus-based EBV vaccines targeting both latent and lytic antigens elicits potent immunity against lethal EBV challenge in humanized miceZhang et al., Emerging Microbes & Infections - PMID: 39387189Product used: PepMix™ EBV (EBNA3b)

Cellular and humoral response to SARS-CoV-2 vaccine BNT162b2 in adults with Chronic Kidney Disease G4/5.Rosdahl et al., New Microbes & New Infections (2024) - PMID: 39282145Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)

MVA-based vaccine candidates expressing SARS-CoV-2 prefusion-stabilized spike proteins of the Wuhan, Beta or Omicron BA. 1 variants protect transgenic K18-hACE2 mice against Omicron infection and elicit robust and broad specific humoral and cellular immune responsesPérez et al., Frontiers in Immunology (2024) - PMID: 39267752Product used: PepMix™ SARS-CoV-2 (Spike B.1.1.529 / BA.1 / Omicron)

SARS-CoV-2 spike-specific nasal-resident CD49a+CD8+ memory T cells exert immediate effector functions with enhanced IFN-γ productionRha et al., Nature Communications (2024) - PMID: 39333516Product used: PepMix™ SARS-CoV-2 (NCAP)

Long-term cellular immunity of vaccines for Zaire Ebola Virus DiseasesWiedemann et al., Nature Communications (2024) - PMID: 39227399Products used: PepMix™ Zaire Ebola (GP/Mayinga-76)

Stem cell memory EBV-specific T cells control EBV tumor growth and persist in vivoPalianina et al., Science Advances (2024) - PMID: 39178248Products used: PepMix™ Collection EBV (25ug/peptide), PepMix™ EBV (LMP2), PepMix™ EBV (BZLF1), PepMix™ EBV (EBNA1), PepMix™ Human Adenovirus 5 (Penton Protein), PepMix™ Human Adenovirus 5 (Hexon Protein), PepMix™ Human CMV (pp65), PepMix™ Human CMV (IE-1), PepMix™ BKV (capsid protein VP1), PepMix™ HHV6 (U90), PepMix™ HHV6 (U54), PepMix™ BKV (large T antigen)

Repeated COVID-19 Vaccination Drives Memory T- and B-cell Responses in Kidney Transplant Recipients: Results From a Multicenter Randomized Controlled TrialMalahe et al., Transplantation (2024) - PMID: 38902860Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)

Impaired T cells and "memory-like" NK-cell reconstitution is linked to late-onset HCMV reactivation after letermovir cessationLauruschkat et al., Blood Advances (2024) - PMID: 38315873Products used: PepMix™ HCMVA (pp65), PepMix™ HIV-1 (NEF) Ultra

Lipo-pam™ adjuvanted herpes zoster vaccine induces potent gE-specific cellular and humoral immune responsesSoo-Kyung Jeong et al., Vaccines (2024) - PMID: 39154056Product used: PepMix™ VZV (gE)

Variant-proof high affinity ACE2 antagonist limits SARS-CoV-2 replication in upper and lower airwaysGagne et al., Nature Communications (2024) - PMID: 39134521Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)

Mucosal adenovirus vaccine boosting elicits IgA and durably prevents XBB.1.16 infection in nonhuman primatesGagne et al., Nature Immunology (2024) - PMID: 39227514Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2), PepMix™ SARS-CoV-2 (NCAP)

Endurance Exercise Does Not Exacerbate Cardiac Inflammation in BALB/c Mice Following mRNA COVID-19 VaccinationEens et al., Vaccines (2024)Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)

Asian Flush Gene Variant Enhances Cellular Immunogenicity of COVID‐19 Vaccine: Prospective Study in the Japanese General PopulationBogahawaththa et al., Vaccines (2024)Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)

Immunogenicity and biodistribution of lipid nanoparticle formulated self-amplifying mRNA vaccines against H5 avian influenzaCui et al., Vaccines (2024) - PMID: 39097672Product used: PepMix™ Influenza A (HA/Indonesia (H5N1))

Infectious diseases and their impact on the development and progression of renal graft dysfunction: Optimizing the preventive approach to viral infectionsDrenko, Dissertation (2024)Products used: PepMix™ Human CMV (IE-1), PepMix™ Human CMV (pp65)

Heterologous mRNA/MVA delivering trimeric-RBD as effectivevaccination regimen against SARS-CoV-2: COVARNA ConsortiumMarcos-Villar et al., Emerging Microbes & InfectionsProduct used: PepMix™ SARS-CoV-2 (S-RBD)

Interleukin‐2‐mediated CD4 T‐cell activation correlates highly with effective serological and T‐cell responses to SARS‐CoV‐2 vaccination in people living with HIVGupta et al., Journal of Medical Virology (2024) - PMID: 39056205Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)

Cytokine profile of anti-spike CD4+ T cells predicts humoral and CD8+ T cell responses after anti-SARS-CoV-2 mRNA vaccinationBenhamouda et al., iScience (2024) Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)

Repeated COVID-19 Vaccination Drives Memory T- and B-cell Responses in Kidney Transplant Recipients: Results From a Multicenter Randomized Controlled TrialMalahe et al., Transplantation (2024) Products used: PepMix SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)

Kinetics of pro- and anti-infammatory spike-specifc cellular immune responses in long-term care facility residents after COVID-19 mRNA primary and booster vaccination: a prospective longitudinal study in JapanKagugawa et al., Immunity and Ageing (2024) - PMID: 38909235Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)

Strategies to determine positive anti-SARS-CoV-2 memory T lymphocyte response during the evolution of an epidemic Nel et al, Journal of Immunological Models (2024)Products used: PepMix SARS-CoV-2 (NCAP), PepMix SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)

Switching disease-modifying therapies from sphingosine-1-phosphate receptor modulators to natalizumab or dimethyl fumarate restores immune responses after SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis Kanakura et al., Clinical Neurology and Neurosurgery (2024) - PMID: 38901377Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)

Intranasal SARS-CoV-2 Omicron variant vaccines elicit humoral and cellular mucosal immunity in female miceSlamaning et al., EBioMedicine (2024) - PMID: 38848648Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein), PepMix™ SARS-CoV-2 (Spike B.1.1.529 / BA.1 / Omicron)

Heightened Epstein-Barr virus immunity and potential cross-reactivities in multiple sclerosisThomas et al., PLoS Pathogens (2024) - PMID: 38843296Products used: PepMix EBV (EBNA1)

Identification of soluble biomarkers that associate with distinct manifestations of long COVIDBuggert et al., Research Square (2024) Product used: PepMix EBV (BARF1), PepMix EBV (BRLF1), PepMix EBV (BMLF1), PepMix EBV (BZLF1), PepMix EBV (EBNA1), PepMix EBV (EBNA2), PepMix EBV (EBNA3a), PepMix EBV (EBNA3b), PepMix EBV (EBNA3c), PepMix EBV (LMP2), PepMix Human CMV (pp65), PepMix Human CMV (IE-2), PepMix Human CMV (IE-1)

A vaccine targeting antigen-presenting cells through CD40 induces protective immunity against Nipah diseasePastor et al., Cell Reports Medicine (2024) - PMID: 38471503Products used: PepMix Nipah Virus (Nucleoprotein N), Nipah virus (Glycoprotein G), Nipah Virus (Fusion Glycoprotein F0) and ECD

Rejection resistant CD30.CAR-modified Epstein-Barr virus specific T cells as an offthe-shelf platform for CD30+ lymphomaQuach et al., Molecular Therapy: Oncology (2024) Products used: PepMix EBV (EBNA1), EBV (BZLF1), EBV (LMP1), EBV (LMP2)

Cytomegalovirus UL44 protein induces a potent T-cell immune response in mice Mancebo et al., Antiviral Research (2024) Products used: Custom PepMix CMV UL44, PepMix Human CMV (pp65)

SARS-CoV-2-specific immune responses converge in kidney disease patients and controls with hybrid immunity Aguilar-Bretones et al., Vaccines (2024) Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)

An IL-10 homologue encoded by human cytomegalovirus is linked with the viral “footprint” in clinical samplesVeld et al., Cytokine (2024) Product used: PepMix Human CMV (IE-1)

Imbalance of SARS-CoV-2-specific CCR6+ and CXCR3+ CD4+ T cells and IFN-γ + CD8+ T cells in patients with Long-COVIDMartínez-Fleta et al., Clinical Immunology (2024) Products used: PepMix SARS-CoV-2 (NCAP), PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)

Optimizing SARS-CoV-2 vaccine responses in kidney transplant recipients: an urgent needCheng et al., Microbiology Spectrum (2024) - PMID: 38747636Products used: PepMix SARS-CoV-2 (Spike B.1.617.2 / Delta), SARS-CoV-2 (Spike B.1.1.529 / BA.2 / Omicron)

Modulation of innate immune response to mRNA vaccination after SARS-CoV-2 infection or sequential vaccination in humansHellgren et al., JCI Insight (2024)Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)

Intranasal vaccination with an NDVvectored SARS-CoV-2 vaccine protects against Delta and Omicron challengesWarner et al., Vaccines (2024) - PMID: 38782986Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)

Kinetics of pro- and anti-inflammatory spike-specific T-cell responses in long-term care facility residents after COVID-19 mRNA primary and booster vaccination: A prospective longitudinal study in JapanKakugawa et al., Research Square (2024)Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)

Nasal vaccination of triple-RBD scaffold protein with flagellin elicits long-term protection against SARS-CoV-2 variants including JN.1Li et al., Signal Transduction and Targeted Therapy (2024) - PMID: 38678055Product used: PepMix SARS-CoV-2 (S-RBD)

Gene replacement therapy in Bietti crystalline corneoretinal dystrophy: an open-label, single-arm, exploratory trialWang et al., Signal Transductions and Targeted Therapy (2024) - PMID: 38653979Product used: PepMix AAV8 (Capsid protein)

A bivalent COVID-19 mRNA vaccine, PTX-COVID19-M1.2, elicited broad immune responses and protected animals from SARS-CoV-2 Omicron subvariants infectionWang et al., Research Square (2024) Products used: PepMix SARS-CoV-2 (Spike B.1.1.529 / BA.4 & BA.5 / Omicron), SARS-CoV-2 (Spike XBB.1.5)

Immunogenicity and Protective Efficacy of Psoralen-Inactivated SARS-CoV-2 Vaccine in Nonhuman PrimatesSanders et al., Vaccines (2024) Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)

Antigen clustering effect on immunogenicity in prefusion-stabilized spike-based COVID-19 vaccinesMatthews et al., Research Square (2024) Product used: PepMix SARS-CoV-2 (Spike Glycoprotein SUB1)

Co-targeting EBV lytic as well as latent cycle antigens increases T-cell potency against lymphomaSharma et al., Blood Advances (2024) Products used: PepMix EBV (BZLF1), EBV (BRLF1), EBV (BMRF1)

Third-party virus specific T cells for the treatment of double stranded DNA viral reactivation and PTLD after solid organ transplantKhoury et al., American Journal of TransplantationProducts used: PepMix EBV (BZLF1), EBV (LMP2), EBV (EBNA1)

Preclinical evaluation of two phylogenetically distant arenavirus vectors for the development of novel immunotherapeutic combination strategies for cancer treatmentRaguz et al., Journal for Immunotherapy of Cancer (2024) - PMID: 38631709Products used: PepMix HPV 16 (E6), HPV 16 (E7)

Lack of functional TCR-epitope interaction is associated with herpes zoster through reduced downstream T cell activationBoeren et al., Cell Reports (2024) - PMID: 38588339Product used: PepMix Influenza A (Neuroamidase /California (H1N1), VZV (gE), VZV (IE62)_2 subpools, VZV (IE63)

COVID-19 vaccination induces distinct T-cell responses in pediatric solid organ transplant recipients and immunocompetent childrenRoznik et al., Vaccines (2024) Products used: PepMix SARS-CoV-2 (Spike Glycoprotein), SARS-CoV-2 (Spike B.1.1.529 / BA.4 & BA.5 / Omicron)

Innate Responses to the Former COVID-19 Vaccine Candidate CVnCoV and Their Relation to Reactogenicity and Adaptive ImmunogenicityWolz et al., Vaccines (2024) Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)

The Micro-Immunotherapy Medicine 2LPAPI® Displays Immune-Modulatory Effects in a Model of Human Papillomavirus Type-16 L1-Protein Capsid-Treated Human Peripheral Blood Mononuclear Cells and Antiproliferative Effects in a Model of Cervical Cancer CellsJacques et al., Cancers (2024) Product used: PepMix HPV16 (L1)

From Vaccination to Infection: Mechanistic Studies of Immune Responses to SARS-COV-2Lenart, Dissertation (2024) Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)

Immunogenicity and efficacy of VLA2001 vaccine against SARS-CoV-2 infection in male cynomolgus macaquesGalhaut et al., Communications Medicine (2024) - PMID: 38570605Products used: PepMix SARS-CoV-2 (S-RBD), SARS-CoV-2 (NCAP)

Evaluation of T Cell Response to SARS-CoV-2 in Kidney Transplant Recipients Receiving Monoclonal Antibody Prophylaxis and the Utility of a Bivalent mRNA Vaccine Booster DoseBertrand et al., Microorganisms (2024) Products used: PepMix SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2), SARS-CoV-2 (NCAP), SARS-CoV-2 (NS7A), SARS-CoV-2 (VEMP), SARS-CoV-2 (VME1), SARS-CoV-2 (Nsp3), CEFX Ultra SuperStim Pool

Carrier-free mRNA vaccine induces robust immunity against SARS-CoV-2 in mice and non-human primates without systemic reactogenicityAbbasi et al., Molecular Therapy (2024) Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)

T cell activation markers CD38 and HLA-DR indicative of non-seroconversion in anti-CD20-treated patients with multiple sclerosis following SARS-CoV-2 mRNA vaccinationVerstegen et al., Multiple Sclerosis (2024) - PMID: 38548324Product used: PepMix SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)

Children treated against lymphoid malignancies display diminished IFN-gamma producing T cells after polyclonal and Varicella zoster virus peptide activationTiselius et al., Research Square (2024) Product used: PepMix VZV (gE) and VZV (IE63)

LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metastatic pancreatic cancer (LOKON001): results from arm 1 of a non-randomised, single-centre, phase 1/2 studyMusher et al., The Lancet Oncology (2024) - PMID: 38547893Product used: PepMix Human Adenovirus 26 (Hexon Protein) and Human Adenovirus 26 (Penton Protein)

Comparable CD8+ T‐cell responses to SARS‐CoV‐2 vaccination in single‐cell transcriptomics of recently allogeneic transplanted patients and healthy individualsTranter et al., Journal of Medical Virology (2024) Product used: CEFX Ultra SuperStim Pool, PepMix SARS-CoV-2 (NCAP), SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2), SARS-CoV-2 AP3A (ORF3a), SARS-CoV-2 NS7A, SARS-CoV-2 NS8, Pan‐SARS-CoV-2 Select, and custom PepMix

Generation of CRISPR-Cas9-edited Tacrolimus-resistant SARS-CoV-2-specific T-cells for adoptive cell therapy in transplant patientsPeter, Dissertation (2024)Products used: PepMix CMVA (pp65), SARS-CoV-2 peptide pools (NCAP, Spike S1, Spike S2, VEMP, VME1, AP3a, NS6, NS7a, NS7b, NS8, ORF9b, ORF10, Y14)

LVS ΔcapB-vectored multiantigenic melioidosis vaccines protect against lethal respiratory Burkholderia pseudomallei challenge in highly sensitive BALB/c miceTullius et al., Vaccines (2024) Product used: PepMix BKV (small T antigen)

Bioinformatic, Biochemical, and Immunological Mining of MHC Class I Restricted T Cell Epitopes for a Marburg Nucleoprotein Microparticle VaccineHarris et al., Vaccines (2024)

Development and Characterization of a Novel DC-Targeting Universal Influenza VaccineOlukitibi et al., Dissertation (2024) Product used: PepMix SARS-CoV-2 (Spike Glycoprotein SUB1)

A vaccine targeting antigen-presenting cells through CD40 induces protective immunity against Nipah disease Pastor et al., Cell Reports Medicine (2024) - PMID: 38471503Products used: PepMix Nipah Virus (Nucleoprotein N), Nipah virus (Glycoprotein G), Nipah Virus (Fusion Glycoprotein F0), custom PepMix Nipah ECD

Single MVA-SARS-2-ST/N Vaccination Rapidly Protects K18-hACE2 Mice against a Lethal SARS-CoV-2 Challenge InfectionClever et al., Viruses (2024) Product used: PepMix SARS-CoV-2 (NCAP), SARS-CoV-2 Antigen Peptide NCAP (LALLLLDRL), Antigen Peptide IFN-gR H-2 Kb (TSYKFESV)

NFκB and NLRP3/NLRC4 inflammasomes regulate differentiation, activation and functional properties of monocytes in response to distinct SARS-CoV-2 proteinsTsukalov et al., Nature Communications (2024) - PMID: 38453949Product used: PepMix SARS-CoV-2 (Spike Glycoprotein SUB1), SARS-CoV-2 (NCAP)

Comparable safety and non-inferior immunogenicity of the SARS-CoV-2 mRNA vaccine candidate PTX-COVID19-B and BNT162b2 in a phase 2 randomized, observer-blinded studyReiter et al., Scientific Reports (2024) - PMID: 38438427Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)

Ad26.M.Env ZIKV vaccine protects pregnant rhesus macaques and fetuses against Zika virus infectionMartinot et al., Research Square (2024) Product used: PepMix ZIKV (E) Ultra, ZIKV (M) Ultra

Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial.Pant et al., Nature Medicine (2024) - PMID: 38195752Product used: PepMix Pan-CMV Select, CMVA (pp65), SARS-CoV-2 (S-RBD)

Cognate Antigen Engagement induces HIV-1 Expression in CD4+ T cells from people in long-term ArtMoskovljevic et al., BioRxiv (2024) Product used: PepMix™ HIV-1 (GAG) Ultra

Bivalent mRNA COVID vaccines elicit predominantly cross-reactive CD4+ T cell clonotypesSop et al., Cell Reports Medicine (2024) - PMID: 38423018Products used: PepMix SARS-CoV-2 (Spike Glycoprotein), SARS-CoV-2 (Spike B.1.1.529 / BA.4 & BA.5 / Omicron)

Immune responses to SARS-CoV-2 mRNA vaccination in people with idiopathic CD4 lymphopeniaRocco et al., Translational and Clinical Immunology (2024) - PMID: 38344971Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)

Multivalent cytomegalovirus glycoprotein B nucleoside modified mRNA vaccines did not demonstrate a greater antibody breadthWang et al., Vaccines (2024) - PMID: 38378950Product used: custom PepStar, PepMix™ CMVA (UL55)

Applying valency-based immuno-selection to generate broadly cross-reactive antibodies against influenza hemagglutininsHinke et al., Nature Communications (2024) - PMID: 38346952Products used: PepMix™ Influenza A (HA/Puerto Rico/8/1934 H1N1), PepMix™ Influenza A (HA /California (H1N1))

Integrating Machine Learning-Enhanced Immunopeptidomics and SARS-CoV-2 PopulationScale Analyses Unveils Novel Antigenic Features for Next-Generation COVID-19 VaccinesCaron et al., Research Square (2024) Product used: PepMix™ HIV-1 (POL) Ultra

Vaccines targeting ESR1 activating mutations elicit anti-tumor immune responses and suppress estrogen signaling in therapy resistant ER+ breast cancerDailey et al., Human Vaccines & Immunotherapeutics (2024) - PMID: 38330990Products used: Custom PepMix (ESR1), PepMix™ HIV-1 (GAG) Ultra

A Gamma-adapted subunit vaccine induces broadly neutralizing antibodies against SARS-CoV-2 variants and protects mice from infectionCoria et al., Nature Communications (2024) - PMID: 38307851Products used: PepMix™ SARS-CoV-2 (S-RBD), PepMix™ SARS-CoV-2 (S-RBD P.1 / Gamma)

Humoral and Cellular Immune Responses against SARS-CoV-2 after Third Dose BNT162b2 following Double-Dose Vaccination with BNT162b2 versus ChAdOx1 in Patients with Cancer Debie et al., Clinical Cancer Research (2024) - PMID: 36341493Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)

Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trialPant et al., Nature Medicine (2024) - PMID: 38195752Products used: PepMix™ SARS-CoV-2 (S-RBD),CEFSX Ultra SuperStim Pool, CEFT Pool, PepMix™ Pan-CMV Select, PepMix CMVA pp65, PepMix™ Pan-EBV Select, CEF Pool (standard)

MVA-based vaccine candidates encoding the native or prefusion-stabilized SARS-CoV-2 spike reveal differential immunogenicity in humansMayer et al., Vaccines (2024) - PMID: 38278816Product used: CEF Pool (extended), PepMix™SARS-CoV-2 (Spike Glycoprotein)

Low pre-existing endemic human coronavirus (HCoV-NL63)-specific T cell frequencies are associated with impaired SARS-CoV-2-specific T cell responses in people living with HIVNg'uni et al., Frontiers in Immunology (2024) - PMID: 38343437Products used: PepMix™ SARS-CoV-2 (Spike B.1.617.2 / Delta), PepMix™ HCoV-NL63 (Spike Glycoprotein), PepMix™ SARS-CoV-2 (Spike B.1.351 / Beta)

T Cell Responses against Orthopoxviruses in HIV-Positive PatientsStefanie et al., Vaccines (2024)Product used: PepMix™ Pan-Poxviridae Select

Caveats of chimpanzee ChAdOx1 adenovirus-vectored vaccines to boost anti-SARS-CoV-2 protective immunity in miceCervantes-Torres et al., Applied Microbiology and Biotechnology (2024) - PMID: 38280035Product used: PepMix™ SARS-CoV-2 (S-RBD B.1.617.2 / Delta)

Comparison of Omicron Breakthrough Infection Versus Monovalent SARS-CoV-2 Intramuscular Booster Reveals Differences in Mucosal and Systemic Humoral ImmunityNantel et al., Mucosal Immunology (2024)Products used: PepMix™SARS-CoV-2 (Spike P.1 / Gamma), PepMix™ SARS-CoV-2 (Spike B.1.351 / Beta), PepMix™ SARS-CoV-2 (Spike B.1.617.2 / Delta), PepMix™ SARS-CoV-2 (Spike B.1.1.7 / Alpha), PepMix™ SARS-CoV-2 (Spike B.1.1.529 / BA.1 / Omicron)

Expanded specific T cells to hypomutated regions of the SARS-CoV-2 using mRNA electroporated antigen presenting cells.Ogando-Rivas et al., Methods and Clinical Development (2024)Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2), PepMix™ SARS-CoV-2 (VME1), PepMix™ SARS-CoV-2 (VEMP), PepMix™SARS-CoV-2 (NCAP)

Enhanced detection of antigen-specific T cells by a multiplexed AIM assayLemieux et al., Cell Rep Methods (2024) - PMID: 38228152Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein), PepMix™ HIV-1 (GAG) Ultra, PepMix™ HIV-1 (POL) Ultra, PepMix™ HIV-1 (ENV) Ultra, PepMix™ HIV-1 (NEF) Ultra, PepMix™ CMVA (pp65)

Three immunizations with Novavax’s protein vaccines increase antibody breadth and provide durable protection from SARSCoV-2Lenart et al., Vaccines (2024) - PMID: 38245545Products used: PepMix™SARS-CoV-2 (Spike Glycoprotein)

Identification of a spike-specific CD8+ T cell epitope following vaccination against the Middle East respiratory syndrome coronavirus in humansHarrer et al., Journal of Infectious Diseases (2024) - PMID: 38195212Products used: PepMix™ MERS-CoV (Spike Glycoprotein), CEF Pool (extended)

Surface-modified measles vaccines encoding oligomeric, prefusion-stabilized SARS-CoV-2 spike glycoproteins boost neutralizing antibody responses to Omicron and historical variants, independent of measles seropositivityMuñoz-Alía et al., mBio (2024) - PMID: 38193729Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)

CD3-downregulation identifies T-helper-cells with superior functionality and distinct metabolism in SARS-CoV2-vaccination- and recall-antigen-specific immunitySattler et al., JCI Insight (2024)Products used: PepMix™ SARS-CoV-2 (Spike B.1.1.7 / Alpha), SARS-CoV-2 Antigen Peptide Spike Fusion (SFIEDLLFNKVTLAD)

Humoral and cellular immune responses after COVID-19 vaccination of lung transplant recipients and patients on the waiting list: a 6-month follow-upHoek et al., Frontiers in Immunology (2024)Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)

Protective MVA-ST Vaccination Robustly Activates T Cells and Antibodies in an Aged-Hamster Model for COVID-19Clever et al., Vaccines (2024)Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)

Optimising a linear ‘Doggybone’ DNA vaccine for influenza virus through the incorporation of DNA targeting sequences and neuraminidase antigenCunliffe et al., Discovery Immunology (2024)'Product used: PepMix Influenza A (Neuroamidase /California (H1N1)

A quest for universal anti-SARS-CoV-2 T cell assay: systematic review, meta-analysis, and experimental validationBinayke et al., NPJ Vaccines (2024) - PMID: 38167915Products used: PepMix SARS-CoV-2 (Spike Glycoprotein), PepMix Pan-SARS-CoV-2 Select

Hepatitis E Virus Epidemiology and Vaccine Response: Studies from Norway and BangladeshØverbø, Dissertation (2023) Product used: PepMix HEV (ORF2)

Ineffective control of Epstein-Barr-virus-induced autoimmunity increases the risk for multiple sclerosisVietzen et al., Cell (2023) - PMID: 38091993Product used: PepMix™ Collection EBV

Evaluation of Luciferase and Prefusion-Stabilized F Protein From Respiratory Syncytial Virus mRNA/LNPs in Pre-Clinical Models Using Jet Delivery Compared to Needle and SyringeMeyer et al., Vaccine (2023) Product used: PepMix™ HRSVA (Fusion Glycoprotein F0)

The immunogenicity and the safety of the adjuvanted glycoprotein E (gE)-based recombinant vaccine against herpes zoster (RZV) in cancer patients during immunotherapyLasagna et al., Human Vaccines & Immunotherapeutics (2023) - PMID: 38037900Products used: PepMix VZV (IE63), PepMix VZV (gE)

Interaction dynamics between innate and adaptive immune cells responding to SARSCoV-2 vaccination in non-human primatesSchramm et al., Nature Communications (2023) - PMID: 38042809Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)

Safety, immunogenicity and efcacy of an mRNA‑based COVID‑19 vaccine, GLB‑COV2‑043, in preclinical animal modelsLelis et al., Scientific Reports (2023) - PMID: 38040905

Production, purification and immunogenicity of Gag virus-like particles carrying SARS-CoV-2 components Gashti et al., Vaccine (2023) - PMID: 38042697Product used: PepMix SARS-CoV-2 (NCAP)

Conjugation of HIV-1 envelope to hepatitis B surface antigen alters vaccine responses in rhesus macaquesNettere et al., Vaccines (2023) - PMID: 38001122Products used: PepMix HBV (Large envelope protein), PepMix HIV-1 (ENV) Ultra

Associations of myeloid cells with cellular and humoral responses following vaccinations in patients with neuroimmunological diseasesWang et al., Nature Communications (2023) - PMID: 38007484Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)

Impaired Cellular and Antibody immunity after COVID-19 in Chronically Immunosuppressed Transplant RecipientsAshokkumar et al., Journal of Surgery and Research (2023)Product used: PepMix SARS-CoV-2 (Spike Glycoprotein SUB2)

Immunotherapy of cytomegalovirus infection by low-dose adoptive transfer of antiviral CD8 T cells relies on substantial post-transfer expansion of central memory cells but not effector-memory cellsHoltappels et al., PLoS Pathogens (2023) Product used: custom PepMix

Hydroxyurea interaction with α7 nicotinic acetylcholine receptor can underlie its therapeutic efficacy upon COVID-19Lykhmus et al., Neuroimmunology (2023) - PMID: 38016403Product used: custom PepMix

Concomitant administration of seasonal influenza and COVID-19 mRNA vaccinesAydillo et al., Emerging Microbes & Infections (2023) - PMID: 38054302Products used: PepMix Influenza A (HA/H1N1/Victoria/2019), Influenza A (HA/H3N2/Darwin/2021), custom PepMix Influenza B Nucleoprotein

A Phase I/II Clinical Trial of Intradermal, Controllable Self-Replicating Ribonucleic Acid Vaccine EXG-5003 against SARS-CoV-2Koseki et al., Vaccines (2023) Product used: PepMix SARS-CoV-2 (S-RBD)

Efectiveness ofVSV vectored SARS‑CoV‑2 spike when administered through intranasal, intramuscular or a combination of bothBeitari et al., Scientific Reports (2023) - PMID: 38049498Products used: PepMix SARS-CoV-2 (Spike Glycoprotein), SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)

Tiza–Titre increase and enhanced immunity through an adjuvanted, recombinant herpes zoster subunit vaccine in patients with liver cirrhosis and post-liver transplantation: a study protocol for a prospective cohort studyVollmer-Raschdorf et al., BMJ Open (2023) Product used: PepMix VZV (gE)

Caracterización del agotamiento de los linfocitos T en pacientes con síndrome Long COVIDBenéitez, Thesis (2023) Products used: PepMix Influenza A (HA/California (H1N1)), custom PepMix Influenza (HA/Perth (H3N2))

Cytomegalovirus-specific T cell immunity reconstitution following allogeneic hematopoietic stem cell transplantation: a pilot studyWang et al., Research Square (2023) Products used: PepMix CMVA (IE-1), PepMix CMVA (pp65)

Immunogenicity of a silica nanoparticle-based SARS-CoV-2 vaccine in miceBarbey et al., European Journal of Pharmaceutics and Biopharmaceutics (2023) - PMID: 37774890Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)

Impaired immune responses and prolonged viral replication in lung allograft recipients infected with SARS‑CoV‑2 in the early phase after transplantationGlueck et al., Infection (2023) - PMID: 37922037Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)

Early humoral and cellular responses after bivalent SARS‐CoV‐2 mRNA‐1273.214 vaccination in long‐term care and retirement home residents in Ontario, Canada: An observational cohort studyBreznik et al., Journal of Medical Virology (2023) - PMID: 37822054Product used: PepMix SARS-CoV-2 (Spike B.1.1.529 / BA.1 / Omicron)

Cytomegalovirus-Specific T Cells in Pediatric Liver Transplant RecipientsGetsuwan et al., Viruses (2023) Products used: PepMix CMVA (IE-1), PepMix CMVA (pp65)

Humoral and Cellular Immunity Are Significantly Affected in Renal Transplant Recipients, Following Vaccination with BNT162b2Fylaktou et al., Vaccines (2023) Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)

Structural surfaceomics reveals an AML-specific conformation of integrin β2 as a CAR T cellular therapy targetMandal et al., Nature Cancer (2023) Products used: PepMix EBV (LMP1), PepMix EBV (EBNA1), PepMix EBV (LMP2), PepMix EBV (BZLF1), PepMix EBV (BRLF1), PepMix CMVA (pp65), PepMix CMVA (IE-1)

SARS-CoV-2 infection establishes a stable and age-independent CD8+ T cell response against a dominant nucleocapsid epitope using restricted T cell receptorsChoy et al., Nature Communications (2023) - PMID: 37872153Product used: PepMix SARS-CoV-2 (Spike Glycoprotein SUB1)

Revaccination of patients with systemic lupus erythematosus or rheumatoid arthritis without an initial COVID-19 vaccine response elicits seroconversion in half of the patientsAmmitzbøll et al., Clinical and Experimental Rheumatology (2023) - PMID: 37877429

An interferon-integrated mucosal vaccine provides pan-sarbecovirus protection in small animal modelsYuen et al., Nature Communications (2023) - PMID: 37875475Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)

Dendritic Cell-Mediated Cross-Priming by a Bispecific Neutralizing Antibody Boosts Cytotoxic T Cell Responses and Protects Mice against SARS-CoV-2Lázaro-Gorines et al., Advanced Science (2023) Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)

Immunology of THymectomy And childhood CArdiac transplant (ITHACA): protocol for a UK-wide prospective observational cohort study to identify immunological risk factors of post-transplant lymphoproliferative disease (PTLD) in thymectomised childrenOffor et al., BMJ Open (2023) - PMID: 37865406Products used: custom PepMix

T regulatory lymphocytes specific for SARS-CoV-2 display increased functional plasticity Esparcia-Pinedo et al., Clinical Immunology - PMID: 37827267Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2), PepMix™ CMVA (pp65)

Immune Profile Determines Response to Vaccination against COVID-19 in Kidney Transplant RecipientsStai et al., Vaccines (2023) - PMID: 37896986Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)

Cytokine profile of anti-spike CD4+T cells predicts humoral and CD8+T cell responses after anti-SARSCoV-2 mRNA vaccinationTartour et al., Research Square (2023) - PMIDProducts used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)

Pretransplant BKV-IgG serostatus and BKV-specific ELISPOT assays to predict BKV infection after kidney transplantationBae et al., Frontiers in Immunology (2023) - PMID: 37809095Products used: PepMix BKV (capsid protein VP1), PepMix BKV (capsid protein VP2), PepMix BKV (capsid protein VP2, isoform VP3)

An RNA-Scaffold Protein Subunit Vaccine for Nasal ImmunizationLam et al., Vaccines (2023) - PMID: 37896953Product used: PepMix SARS-CoV-2 (S-RBD)

Selection of cross-reactive T cells by commensal and food-derived yeasts drives cytotoxic TH1 cell responses in Crohn’s diseaseMartini et al., Nature Medicine (2023) - PMID: 37749331Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)

Preexisting Enhancing Antibodies in Vaccinated Participants Accelerate Dengue Virus 1 Infection Following Live Virus Human ChallengeLyke et al., Research Square (2023) Product used: Custom PepMix

Enhanced Omicron subvariant cross-neutralization efficacy of a SARS-CoV-2 BA.4/5 mRNA vaccine encoding a noncleaved, nonfusogenic spike antigenOh et al., Research Square (2023) Product used: PepMix SARS-CoV-2 (Spike B.1.1.529 / BA.4 & BA.5 / Omicron)

Spontaneous HIV expression during suppressive ART is associated with the magnitude and function of HIVspecific CD4+ and CD8+ T cellsDubé et al., Cell Hosts Microbe (2023) - PMID: 37708853Products used: PepMix SARS-CoV-2 (Spike Glycoprotein)

Responses of patients with cancer to mRNA vaccines depend on the time interval between vaccination and last treatmentDonhauser et al., Journal for ImmunoTherapy of Cancer - PMID: 37730271Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)

Long-term humoral and cellular immunity after primary SARS-CoV-2 infection: A 20- month longitudinal studyHvidt et al., Research Square (2023) - PMID: 37974069Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)

SARS-CoV-2 variants of concern elicit divergent early immune responses in hACE2 transgenic miceFricke et al., European Journal of Immunology (2023) - PMID: 37609807Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)

A cell-free antigen processing system informs HIV-1 epitope selection and vaccine designSengupta et al., Journal of Experimental Medicine (2023) - PMID: 37058141Products used: PepMix HIV-1 (NEF) Ultra, HIV-1 (Con B gag motif)

Lymph node dendritic cells harbor inducible replication-competent HIV despite years of suppressive ART Banga et al., Cell Host & Microbe (2023) - PMID: 37751747

Ablative radiation alone in stage I lung cancer produces an adaptive systemic immune response: insights from a prospective studyVoong et al., Journal for ImmunoTherapy of Cancer (2023) Products used: CEFX Ultra SuperStim Pool MHC-II Subset & PepMix™ HIV-1 (GAG) Ultra

Enhancing Anti-SARS-CoV-2 Neutralizing Immunity by Genetic Delivery of Enveloped Virus-like Particles Displaying SARS-CoV-2 SpikesYang et al., Vaccines (2023) Products used: PepMix SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)

Early Omicron infection is associated with increased reinfection risk in older adults in long-term care and retirement facilitiesBreznik et al., The Lancet (2023) Product used: PepMix SARS-CoV-2 (Spike B.1.1.529 / BA.1 / Omicron)

First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b/2 trialThibaudin et al., Nature Medicine (2023) - PMID: 37563240Products used: PepMix Human (NY-ESO-1)

Intradermal administration of DNA vaccine targeting Omicron SARS‑CoV‑2 via pyro‑drive jet injector provides the prolonged neutralizing antibody production via germinal center reactionHayashi et al., Scientific Reports (2023) - PMID: 37563266Products used: PepMix SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2), SARS-CoV-2 (Spike B.1.1.529 / BA.1 / Omicron)

Lymph node targeted multi-epitope subunit vaccine promotes effective immunity to EBV in HLA-expressing miceDasari et al., Nature Communications (2023) - PMID: 37553346Products used: PepMix EBV (GP350/GP340)

Safety and immunogenicity of a SARS-CoV-2 Gamma variant RBD-based protein adjuvanted vaccine used as booster in healthy adultsPasquevich et al., Nature Communications (2023) Product used: PepMix SARS-CoV-2 (S-RBD P.1 / Gamma)

Zika virus infection during pregnancy and vertical transmission: case reports and peptide-specic cellmediated immune responsesSoudeyns et al., Research Sqaure (2023) Products used: PepMix CMVA (pp65), ZIKV (NS1) Ultra, ZIKV (C) Ultra, ZIKV (E) Ultra

YF17D-vectored Ebola vaccine candidate protects mice against lethal surrogate Ebola and yellow fever virus challengeLemmens et al., Vaccines (2023) Product used: PepMix Zaire Ebola (GP/Kikwit-95)

Breadth and Durability of SARS-CoV-2-Specific T Cell Responses following Long-Term Recovery from COVID-19Dang et al., Microbiology Spectrum (2023) - PMID: 37428088Products used: PepMix SARS-CoV-2 (Spike Glycoprotein), SARS-CoV-2 (NCAP), SARS-CoV-2 (VEMP), SARS-CoV-2 (VME1), SARS-CoV-2 (ORF10), SARS-CoV-2 (ORF9B)Custom PepMix : SARS-CoV-2 ORF3a, ORF6, ORF7a, ORF7b, ORF8

A localizing nanocarrier formulation enables multi-target immune responses to multivalent replicating RNA with limited systemic inflammationKimura et al., Molecular Therapy (2023) - PMID: 37403357Product used: PepMix™ SARS-CoV-2 (Spike B.1.351 / Beta)

Unmodified rabies mRNA vaccine elicits high cross-neutralizing antibody titers and diverse B cell memory responsesHellgren et al., Nature Communications (2023) - PMID: 37349310Product used: PepMix Rabies virus (Glycoprotein)

Immunological imprinting of humoral immunity to SARS-CoV-2 in childrenDowell et al., Nature Communications - PMID: 37386081Product used: PepMix™ SARS-CoV-2 (Spike B.1.1.529 / BA.1 / Omicron) & Influenza A (MP1 (H3N2))

Adjuvant lipidoid-substituted lipid nanoparticles augment the immunogenicity of SARS-CoV-2 mRNA vaccinesHan et al., Nature Nanotechnology (2023) - PMID: 37365276Products used: PepMix™ SARS-CoV-2 (S-RBD)

Characterization of T cell responses to SARS-CoV-2 following infection and vaccinationLaw, Dissertation (2023)Products used: PepMix™SARS-CoV-2 (VME1), SARS-CoV-2 (VEMP), SARS-CoV-2 (NCAP) & SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)

Oligosymptomatic long-term carriers of SARS-CoV-2 display impaired innate resistance but increased high-affinity anti-Spike antibodiesMontes-Cobos et al., iScience (2023) Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)

Early evaluation of the safety, reactogenicity, and immune response after a single dose of modified vaccinia Ankara–Bavaria Nordic vaccine against mpox in children: a national outbreak responseLadhani et al., The Lancet (2023) - PMID: 37336224Product used: Custom PepMix

Third and Fourth Vaccine Doses Broaden and Prolong Immunity to SARSCoV-2 in Adult Patients with Immune-Mediated Inammatory DiseasesCheung et al., Journal of Immunology (2023) - PMID: 37326480Product used: PepMix SARS-CoV-2 (Spike B.1.1.529 / BA.4 & BA.5 / Omicron)

T-Cell-Dominated Immune Response Resolves Protracted SARS-CoV-2 Infection in the Absence of Neutralizing Antibodies in an Immunocompromised IndividualBunse et al., Microorganisms (2023) - PMID: 37375064Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)

Engineered tumor-specific T cells using immunostimulatory photothermal nanoparticlesSweeney et al., Cytotherapy (2023) - PMID: 37278683Products used: custom PepMix

High efficacy of VLA2001 vaccine against SARSCoV-2 infection in non-human primatesLe Grand et al., Research Square (2023) Products used: PepMix™ SARS-CoV-2 (S-RBD) & SARS-CoV-2 (NCAP)

A novel multi-antigenic parapoxvirus-based vaccine demonstrates efficacy in protecting hamsters and non-human primates against SARS-CoV-2 challengeReguzova et al., Research Square et al., (2023) Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein) & SARS-CoV-2 (NCAP)

The Influence of Adjuvant Type on the Immunogenicity of RBD/N Cocktail Antigens as a Vaccine Candidate against SARS-CoV-2 VirusBrzuska et al., Microbiology Spectrum (2023) - PMID: 37199661Product used: PepMix™ SARS-CoV-2 (S-RBD)

The effects of exercise training for eight weeks on immune cell characteristics among breast cancer survivorsEcharri et al., Frontiers Sports Act. Living (2023) - PMID: 37252426Product used: PepMix™ CMVA (pp65) & VZV (IE63)

Specific immune response to mRNA vaccines against COVID-19 in patients receiving allogeneic stem cell transplantation for myeloid malignancy was altered by immunosuppressive therapy Macková et al., Leukemia Research (2023) - PMID: 37216792Product used: PepMix™ SARS-CoV-2 (NCAP)

Robust Vaccine-Induced as Well as Hybrid B- and T-Cell Immunity across SARS-CoV-2 Vaccine Platforms in Peoplen with HIVVerburgh et al., Microbiology Spectrum (2023) - PMID: 37166335Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein) & SARS-CoV-2 (NCAP)

A protective, single-visit TB vaccination regimen by co-administration of a subunit vaccine with BCGDijkman et al., Vaccines (2023) - PMID: 37160970Product used: PepMix M. tuberculosis (ESAT-6), M. tuberculosis (PPE68), M. tuberculosis (EspA), PepMix M. tuberculosis (MPT64) & custom PepMix (for EspI, EspC, MPT70, MPT83),

Pre-pandemic SARS-CoV-2-specific IFN-γ and antibody responses were low in Ugandan samples and significantly reduced in HIV-positive specimensNantambi et al., Frontiers in Immunology (2023) - PMID: 37153598Product used: PepMix™ SARS-CoV-2 (Spike Glycoproteins)

High-dimensional analysis of 16 SARS-CoV-2 vaccine combinations reveals lymphocyte signatures correlating with immunogenicityNuñez et al., Nature Immunology (2023) - PMID: 37095378Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein) & SARS-CoV-2 (NCAP)

Impact of age and comorbidities on SARS-CoV-2 vaccine-induced T cell immunityDietz et al., Communications Medicine (2023) - PMID: 37095240Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)

ESCRT recruitment to SARS-CoV-2 spike induces virus-like particles that improve mRNA vaccinesHoffmann et al., Cell (2023) - PMID: 37146611Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)

COVID-19 relapse associated with SARS-CoV-2 evasion from CD4+ T-cell recognition in an agammaglobulinemia patientMorita et al., iScience (2023) - PMID: 37124420Products used: 27 structural and non-structural PepMix SARS-CoV-2 proteins

Naive T cells inhibit the outgrowth of intractable antigen-activated memory T cells: implications for T-cell immunotherapySharma et al., Journal for Immunotherapy of Cancer (2023) - PMID: 37072346Product used: PepMix™ EBV (EBNA1), EBV (LMP1), EBV (LMP2) & EBV (BARF1)

Exercise mobilizes diverse antigen specific T-cells and elevates neutralizing antibodies in humans with natural immunity to SARS CoV-2Baker et al., Brain, Behaviour & Immunity (2023) - PMID: 36743994Products used: PepMix™ Human (Actin) & SARS-CoV-2 (Spike Glycoprotein)

A cell-free antigen processing system informs HIV-1 epitope selection and vaccine designSengupta et al., Journal of Experimental Medicine (2023) - PMID: 37058141Product used: PepMix™ HIV-1 (NEF) Ultra & HIV-1 (Con B gag motif)

Long-Term Follow-Up after Adoptive Transfer of BK-Virus-Specific T Cells in Hematopoietic Stem Cell Transplant RecipientsKoldehoff et al., Vaccines (2023) - PMID: 37112757Product used: PepMix™ BKV (capsid protein VP1) & BKV (large T antigen)

Metabolic interventions improve HBV envelope-specific T-cell responses in patients with chronic hepatitis BFu et al., Hepatology International (2023) - PMID: 36976426Product used: PepMix™ HBV (Capsid Protein) Ultra & HBV (LEP) Ultra

Omicron BA.4/5 neutralization and T-cell responses in organ transplant recipients after Booster mrna vaccine: a Multicenter Cohort StudyFerreira et al., Clinical Infectious Diseases (2023) - PMID: 36975097Product used: PepMix SARS-CoV-2 (Spike B.1.1.529 / BA.4 & BA.5 / Omicron)

Cytotoxic T Cells Targeting Spike Glycoprotein Are Associated with Hybrid Immunity to SARS-CoV-2Phan et al., Journal of Immunology (2023) - PMID: 36961450Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein) & SARS-CoV-2 (NCAP)

Combination Ad26.RSV.preF/preF protein vaccine induces superior protective immunity compared with individual vaccine components in preclinical modelsSaeland et al., Vaccines (2023) - PMID: 36949051Product used: PepMix HRSVA (Fusion Glycoprotein F0)

Humoral and cellular immunity to SARS-CoV-2 after vaccination with mRNA vaccines in PLWH with discordant immune response. Influence on the vaccine administered López-Cortés et al., Frontiers in Immunology (2023) - PMID: 37006309Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)

SARS-CoV-2 spike-ferritin-nanoparticle adjuvanted with ALFQ induces long-lived plasma cells and cross-neutralizing antibodiesShrivastava et al., Vaccines (2023) - PMID: 36934088Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)

Immunogenicity of COVID-eVax Delivered by Electroporation Is Moderately Impacted by Temperature and Molecular IsoformsD'Alessio et al., Vaccines (2023) - PMID: 36992261Product used: PepMix™ SARS-CoV-2 (S-RBD)

Spezifische T-Zellantwort und Immunevasion beim humanen Herpesvirus 6 und SARS-CoV-2Hollaus, Dissertation (2023)

Engineering potent live attenuated coronavirus vaccines by targeted inactivation of the immune evasive viral deubiquitinaseMyeni et al., Nature Communications (2023) Product used: PepMix MERS-CoV (Spike Glycoprotein)

Schistosoma mansoni infection alters the host pre-vaccination environment resulting in blunted Hepatitis B vaccination immune responses.Muir et al., MedRxiv (2023) Product used: PepMix HBV (Large envelope protein)

A systems immunology study comparing innate and adaptive immune responses in adults to COVID-19 mRNA and adenovirus vectored vaccinesRyan et al., Cell Reports Medicine (2023) Product used: PepMix Chimpanzee Adenovirus Y25 (Hexon Protein)

Incorporation of SARS-CoV-2 spike NTD to RBD Protein Vaccine Improves Immunity Against Viral VariantsMontgomerie et al., IScience (2023) Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)

Pyrimidine de novo synthesis inhibition selectively blocks effector but not memory T cell developmentScherer et al., Nature Immunology (2023) Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)

Carbohydrate fatty acid monosulphate: oil-in-water adjuvant enhances SARS-CoV-2 RBD nanoparticle-induced immunogenicity and protection in miceNanishi et al., Vaccines (2023) Product used: PepMix SARS-CoV-2 (S-RBD)

Efficacy of an unmodified bivalent mRNA vaccine against SARS-CoV-2 variants in female small animal modelsCorleis et al., Nature Communications (2023) Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)

The role of the T-cell mediated immune response to Cytomegalovirus infection in intrauterine transmissionSoriano-Ramos et al., PLOS One (2023) Products used: PepMix CMVA (IE-1) & CMVA (pp65)

Multimodal single‑cell analyses of peripheral blood mononuclear cells of COVID‑19 patients in JapanKashima et al., Scientific Reports (2023) - PMID: 36732528Products used: PepMix SARS-CoV-2 (Spike Glycoprotein), SARS-CoV-2 (NCAP), SARS-CoV-2 (VEMP), SARS-CoV-2 (VME1), ....ORF3a/6/7a/7b/8/9b/10

Trimeric, APC-Targeted Subunit Vaccines Protect Mice against Seasonal and Pandemic InfluenzaTjärnhage et al., Journal of Virology (2023) Products used: PepMix Influenza A (HA/Puerto Rico/8/1934 H1N1) & Influenza A (HA /California (H1N1))

Anti-SARS-CoV-2 cellular response after 2 and 3 doses of BNT162b2 mRNA vaccine in lymphoma patients receiving anti-CD20 antibodiesGressens et al., Vaccines (2023) Product used: PepMix SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)

Long COVID manifests with T cell dysregulation, inflammation, and an uncoordinated adaptive immune response to SARS-CoV-2Yin et al., BioRxiv (2023) Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)

Exercise mobilizes diverse antigen specific T-cells and elevates neutralizing antibodies in humans with natural immunity to SARS CoV-2Baker et al., Brain Behaviour & Immunity - Health (2023) Products used: PepMix Human (Actin) & SARS-CoV-2 (Spike Glycoprotein)

The HDAC inhibitor zabadinostat is a systemic regulator of adaptive immunityLiu et al., Communications Biology (2023)Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)

SARS-CoV-2 Omicron BA.4/BA.5 Mutations in Spike Leading to T Cell Escape in Recently Vaccinated IndividualsEmmelot et al., Viruses (2023)

Immunogenicity and safety of a two-dose regimen with hepatitis E virus vaccine in healthy adults in rural Bangladesh: A randomized, double-blind, controlled, phase 2/pilot trialØverbø et al., Vaccine (2023) Product used: PepMix HEV (ORF2)

A linear DNA encoding the SARS-CoV-2 receptor binding domain elicits potent immune response and neutralizing antibodies in domestic catsConforti et al., Molecular Therapy (2023) Product used: PepMix SARS-CoV-2 (S-RBD)

Immunogenicity and safety of Biological E’s CORBEVAX™ vaccine as a heterologous booster dose in adult volunteers previously vaccinated with two doses of either COVISHIELD™ or COVAXIN: A Prospective double-blind randomised hase III clinical study Thuluva et al., MedRxiv (2023)Product used: PepMix SARS-CoV-2 (S-RBD)

The prospect of universal coronavirus immunity: a characterization of reciprocal and non-reciprocal T cell responses against SARS-CoV2 and common human coronavirusesSoni et al., BioRxiv (2023)

Assessment of Immunogenicity and Efficacy of CV0501 mRNA-based Omicron COVID-19 Vaccination in Small Animal ModelsRoth et al., BioRxiv (2023)Product used: PepMix SARS-CoV-2 (Spike B.1.1.529 / BA.1 / Omicron)

Diminished responses to mRNA-based SARS-CoV-2 vaccines in individuals with rheumatoid arthritis on immune modifying therapies Klebanoff et al., MedRxiv (2023) Products used: CEFX Ultra SuperStim Pool, PepMix SARS-CoV-2 (Spike Glycoprotein)

An inactivated SARS-CoV-2 vaccine induced cross-neutralising persisting antibodies and protected upon challenge in small animalsOffersgaard et al., iScience (2023)Products used: SARS-CoV-2 (Spike Glycoprotein), SARS-CoV-2 (S-RBD), SARS-CoV-2 (NCAP), SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)

Safety, tolerability, and immunogenicity of a new SARS-CoV-2 recombinant Gamma variant RBD-based protein adjuvanted vaccine, used as heterologous booster in healthy adults: a Phase 1 interim reportPasquevich et al., MedRxiv (2023)Product used: PepMix SARS-CoV-2 (S-RBD P.1 / Gamma)

Single-dose YF17D-vectored Ebola vaccine candidate protects mice against both lethal surrogate Ebola and yellow fever virus challenge Lemmens et al., BioRxiv (2023)Products used: PepMix Zaire Ebola (GP/Kikwit-95), Yellow fever (NS4B)

Persistence of SARS-CoV-2 neutralizing antibodies and anti-Omicron IgG induced by BNT162b2 mRNA vaccine in patients with autoimmune inflammatory rheumatic disease: An explanatory study in JapanYamaguchi et al., The Lancet (2023) Product used: PepMix SARS-CoV-2 (Spike), SARS-CoV-2 (Spike B.1.1.529 / BA.1 / Omicron)

Potent high-avidity neutralizing antibodies and T cell responses after COVID-19 vaccination in individuals with B cell lymphoma and multiple myelomaKeppler-Hafkemeyer et al., Nature Cancer (2023) - PMID: 36543907Products used: PepMix SARS-CoV-2 (Spike B.1.617.2 / Delta), Human Adenovirus 5 (Hexon Protein), HCoV-OC43 (Spike Glycoprotein), SARS-CoV-2 (NCAP)

Listeria-vectored multi-antigenic tuberculosis vaccine protects C57BL/6 and BALB/c mice and guinea pigs against Mycobacterium tuberculosis challengeJia et al., Communications Biology (2022) Products used: PepMix M. tuberculosis (Ag85B), M. tuberculosis (EspA), M. tuberculosis (EsxN), M. tuberculosis (TB8.4), M. tuberculosis (MPT64), custom PepMix (EsxH, EsxB, EsxA, ppe68)

A novel intradermal tattoo-based injection device enhances the immunogenicity of plasmid DNA vaccinesGomez et al., Vaccines (2022) - PMID: 36543794Products used: PepMix Zaire Ebola (GP/Mayinga-76)

Longitudinal adaptive immune responses following sequential SARS-CoV-2 vaccinations in MS patients on anti-CD20 therapies and sphingosine-1-phosphate receptor modulatorsSabatino et al., Multiple Sclerosis and Related Disorders (2022) Products used: PepMix SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)

Comprehensive Analysis of Epstein-BarrVirus LMP2A-Specific CD8+ and CD4+ T Cell Responses Restricted to Each HLA Class I and II Allotype Within an IndividualJo et al., Immune Network (2022) Product used: PepMix EBV (LMP2)

Accelerated waning of immune responses to a third COVID-19 vaccination in patients with immune-mediated inflammatory diseases Mrak et al., Journal of Autoimmunity (2022) Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein), SARS-CoV-2 (Spike B.1.1.529 / BA.1 / Omicron)

Characterization of Three Variants of SARS-CoV-2 In Vivo Shows Host-Dependent Pathogenicity in Hamsters, While Not in K18-hACE2 MiceToomer et al., Viruses (2022) - PMID: 36423193

Product used: PepMix SARS-CoV-2 (Spike B.1.1.529 / BA.1 / Omicron)

High antibody levels and reduced cellular response in children up to one year after SARS-CoV-2 infectionJacobsen et al., Nature Communications (2022) Products used: PepMix SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)

Allogeneic, Off-the-Shelf, SARS-CoV-2-specific T cells (ALVR109) for the treatment of COVID-19 in high risk patientsVasileiou et al., Haemtologica (2022) Products used: PepMix SARS-CoV-2 (NCAP), SARS-CoV-2 (VME1), SARS-CoV-2 (VEMP), SARS-CoV-2 (Spike Glycoprotein), SARS-CoV-2 (NS7A), SARS-CoV-2 (NS7B), SARS-CoV-2 (NS8)

SARS-CoV-2-Spike Antibody and T-Cell Responses Elicited by a Homologous Third mRNA COVID-19 Dose in Hemodialysis and Kidney Transplant RecipientsPanizo et al., Microorganisms (2022) Product used: PepMix SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)

Combined plasma cell-free DNA detection and IFNγ/TNF-α dual fluorospot assays for diagnosing active tuberculosisKim et al., Research Square (2022)Products used: PepMix M. tuberculosis (ESAT-6), M. tuberculosis (CFP-10), M. tuberculosis (Ag85B)

Four-Parameter FluoroSpot Assay Reveals That the Varicella Zoster Virus Elicits a Robust Memory T Cell IL-10 Response throughout ChildhoodNilsson et al., Journal of Virology (2022) - PMID: 36314824Products used: PepMix VZV (IE63) & VZV (gE)

Characterization of B-cell and T-cell responses to a tetravalent dengue purified inactivated vaccine in healthy adultsFriberg et al., Vaccines (2022) - PMID: 36316335Product used: PepMix Dengue 1 (E) Ultra

Reduced humoral but stable cellular SARS-CoV-2-specific immunity in liver transplant recipients in the first year after COVID-19Kirchner et al., PLoS One (2022) - PMID: 36322587Products used: PepMix Pan-SARS-CoV-2 Select, SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2), SARS-CoV-2 (NCAP), SARS-CoV-2 (VEMP), HCoV-229E (Spike Glycoprotein), HCoV-OC43 (Spike Glycoprotein), HRSVB (Nucleocapsid Protein N), Influenza A (M1) Ultra

Efficacy of mucosal vaccination using a protozoan parasite as a vehicle for antigen delivery: IgG and neutralizing response after rectal administration of LeCoVax-2, a candidate vaccine against COVID-19Epis et al., Pharmacological Research (2022) - PMID: 36336215Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)

Immunological signature in human cases of monkeypox infection in 2022 outbreak: an observational studyAgrati et al., The Lancet (2022)Products used: PepMix Vaccinia virus (MVA105L), Vaccinia virus (MVA074R), Vaccinia virus (MVA121L)

SARS-CoV-2 Spike-specific IFN-gamma T-cell Response After COVID-19 Vaccination in Patients With Chronic Kidney Disease, on Dialysis, or Living With a Kidney TransplantImhof et al., Infectious Disease (2022) Products used: PepMix SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)

Chimeric mRNA based COVID-19 vaccine induces protective immunity against Omicron and Delta variantsHu et al., Molecular Therapy (2022) Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)

Humoral and Cellular Responses to a Delayed Fourth SARS-CoV-2 mRNA-Based Vaccine in Weak Responders to 3 Doses Kidney Transplant RecipientsDel Bello et al., Vaccines (2022) - PMID: 36146517Product used: PepMix SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)

A third dose of the unmodified COVID-19 mRNA vaccine CVnCoV enhances quality and quantity of immune responsesLenart et al., Molecular Therapy (2022) Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)

A Tale Of T ale Of Two Transgenes: Aa ansgenes: Aav-Dystr v-Dystrophin And Aa ophin And Aav-Spike Reveal Common Themes For Gene Therapy And Vaccines Greer, Dissertation (2022) Products used: PepMix SARS-CoV-2 (Spike Glycoprotein) and SARS-CoV-2 (Spike B.1.1.7 / Alpha)

Immunogenicity of SARS-CoV-2 spike antigens derived from Beta & Delta variants of concernAkache et al., Vaccines (2022) Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)

Artificial Cell Membrane Polymersome-Based Intranasal Beta Spike Formulation as a Second Generation Covid-19 VaccineLam et al., ACS Nano (2022) -Products used: PepMix SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)

Signs of immunosenescence correlate with poor outcome of mRNA COVID-19 vaccination in older adultsPalacios-Pedrero et al., Nature Aging (2022) Product used: PepMix SARS-CoV-2 (NCAP)

Rekombinowane cząstki wirusopodobne jako potencjalne antygeny szczepionkowe przeciwko wirusowi Zika Brzuska, Dissertation (2022)Products used: PepMix ZIKV (E) Ultra and ZIKV (M) Ultra

Early intervention with 3BNC117 and romidepsin at antiretroviral treatment initiation in people with HIV-1: a phase 1b/2a, randomized trialGunst et al., Nature Medicine (2022) - PMID: 36253609Product used: PepMix HIV Gag Ultra

NVX-CoV2373-induced cellular and humoral immunity towards parental SARS-CoV-2 and VOCs compared to BNT162b2 and mRNA-1273-regimensHielscher et al., Journal of Clinical Virology (2022) - PMID: 36279695Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)

Immune Response after the Fourth Dose of SARS-CoV-2 mRNA Vaccine Compared to Natural Infection in Three Doses’ Vaccinated Solid Organ Transplant RecipientsBusà et al., Vaccines (2022) - PMID: 36298854Product used: PepMix SARS-CoV-2 (Spike Glycoprotein), SARS-CoV-2 (NCAP) and CEFX Ultra SuperStim Pool

Proinflammatory Innate Cytokines and Distinct Metabolomic Signatures Shape the T Cell Response in Active COVID-19Binayke et al., Vaccines (2022) - PMID: 36298628Product used: PepMix SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)

Persistent T cell-mediated immune responses against Omicron variants after the third COVID-19 mRNA vaccine doseBelik et al., Research Square (2022) Products used: PepMix SARS-CoV-2 (Spike Glycoprotein), SARS-CoV-2 (Spike B.1.1.529 / BA.1 / Omicron), and SARS-CoV-2 (Spike B.1.1.529 / BA.2 / Omicron)

Administration of broadly neutralizing anti-HIV-1 antibodies at ART initiation maintains long-term CD8+ T cell immunityRosás-Umbert et al., Nature Communications (2022)Products used: PepMix HIV-1 (GAG) Ultra, HIV-1 (ENV) Ultra, HIV-1 (NEF) Ultra, HIV-1 (POL) Ultra

Ablation of CD8+ T cell recognition of an immunodominant epitope in SARS-CoV-2 Omicron variants BA.1, BA.2 and BA.3Swaminathan et al., Nature Communications Products used: PepMix SARS-CoV-2 (NCAP), SARS-CoV-2 (NS6), SARS-CoV-2 (NS7A), SARS-CoV-2 (NS7B), SARS-CoV-2 (NS8), SARS-CoV-2 (ORF9B), SARS-CoV-2 (ORF10), SARS-CoV-2 (Spike Glycoprotein), SARS-CoV-2 (VEMP), SARS-CoV-2 (VME1), SARS-CoV-2 (Y14)

Accumulation of mutations in antibody and CD8 T cell epitopes in a B cell depleted lymphoma patient with chronic SARS-CoV-2 infectionKhatamzas et al., Nature Communication (2022) Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)

Evidence of premature lymphocyte aging in people with low anti-spike antibody levels after BNT162b2 vaccinationHuang et al., iScience (2022) - PMID: Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)

SARS-CoV-2-specicific humoral immunity in convalescent patients with mild COVID-19 is supported by CD4+ T-cell help and negatively correlated with Alphacoronavirus-specific antibody titerOdendahl et al., Immunology Letters (2022) Product used: PepMix CMVA (pp65)

Comparison of the Immune Responses to COVID-19 Vaccines in Bangladeshi PopulationSarker et al., Vaccines (2022) Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)

Comparison between enzyme‐linked immunospot assay and intracellular cytokine flow cytometry assays for the evaluation of T cell response to SARS‐CoV‐2 after symptomatic COVID‐19Villemonteix et al., Immunity, Inflammation and Disease (2022) - PMIDPepMix SARS-CoV-2 (Spike Glycoprotein), SARS-CoV-2 (NCAP)

Dual spike and nucleocapsid mRNA vaccination confer protection against SARS-CoV-2 Omicron and Delta variants in preclinical modelsHajnik et al., Science Translational medicine (2022) - PMID: 36103514Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)

A Recombinant VSV-Based Bivalent Vaccine Effectively Protects against Both SARS-CoV-2 and Influenza A Virus InfectionAo et al., Journal of Virology (2022) - PMID: 36069551Product used: PepMix SARS-CoV-2 (Spike Glycoprotein SUB1)

SARS-CoV-2 mRNA-vaccine candidate; COReNAPCIN, induces robust humoral and cellular immunity in mice and non-human primatesAlimohammadi et al., Vaccines (2022) - PMID: 36056015Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)

SARS‑CoV‑2‑reactive IFN‑γ‑producing CD4+ and CD8+T cells in blood do not correlate with clinical severity in unvaccinated critically ill COVID‑19 patientsOlea et al., Scientific Reports (2022) - PMID: 35995830

Immune response to SARS-CoV-2 mRNA vaccination and booster dose in patients with multiple myeloma and monoclonal gammopathies: impact of Omicron variant on the humoral responseStort et al., Oncoimmunology (2022) Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)

Humoral and cellular responses to mRNA-based COVID-19 booster vaccinations in patients with solid neoplasms under active treatmentSu et al., ESMO Open (2022)Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)

Protective Immunity of COVID-19 Vaccination with ChAdOx1 nCoV-19 Following Previous SARS-CoV-2 Infection: A Humoral and Cellular InvestigationAzamor et al., Viruses (2022) - PMID: 36146723Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)

Antibody and T-cellular response to COVID-19 booster vaccine in SARS-CoV-1 survivorsLu et al., Clinical Immunology (2022) Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)

Immunogenicity and safety of a fourth COVID-19 vaccination in rituximab-treated patients: an openlabel extension studyMrak et al., Annals of Rheumatic Disease (2022) - PMID: 35977809

Gene Transfer in Adeno-Associated Virus Seropositive Rhesus Macaques Following Rapamycin Treatment and Subcutaneous Delivery of AAV6, but Not Retargeted AAV6 VectorsStone et al., Human Gene Therapy (2022)

SARS-CoV-2-specific CD4+ T cell longevity correlates with Th17-like phenotypeTerahara et al., iScience (2022) - PMID: 35992306

Japanese encephalitis virus infection in its natural amplification and reservoir host, the pigRedant, Dissertation (2022)

Secreted heat shock protein gp96-Ig and OX40L-Fc combination vaccine enhances SARS-CoV-2 Spike (S) protein-specific B and T cell immune responsesPadula et al., Vaccine: X (2022) - PMID: 35936992Products used: PepMix SARS-CoV-2 (Spike Glycoprotein SU1 & SU2)

Analysis of the Specific Immune Response after the Third Dose of mRNA COVID-19 Vaccines in Organ Transplant Recipients: Possible Spike-S1 Reactive IgA Signature in Protection from SARS-CoV-2 InfectionMiele et al., Microorganisms (2022) Products used: PepMix SARS-CoV-2 (Spike Glycoprotein SU1 & SU2) & SARS-CoV-2 NCAP

mRNA booster vaccination protects aged mice against the SARS-CoV-2 Omicron variantNanishi et al., Communications Biology (2022)

Lower vaccine-acquired immunity in the elderly population following two-dose BNT162b2 vaccination is alleviated by a third vaccine doseRenia et al., Nature Communications

The long term vaccine-induced anti-SARS-CoV-2 immune response is impaired in quantity and qualityunder TNFα blockadeGeisen et al., Journal of Medical Virology (2022) - PMID: 35945627

Clinical outcomes, immunogenicity, and safety of BNT162b22 Vaccine in Primary Antibody DeficiencyMilota et al., Authorea (2022)

DNA-Vaccine-Induced Immune Response Correlates with Lower Viral SARS-CoV-2 Titers in a Ferret ModelCompagnone et al., Vaccines (2022) - PMID: 35893826

SARS-CoV-2 Vaccine-Induced Antibody and T-Cell Response in SARS-CoV-1 SurvivorsDuan et al., Cell Reports (2022)

Comparative immunogenicity and reactogenicity of heterologous ChAdOx1-nCoV-19-priming and BNT162b2 or mRNA1273-boosting with homologous COVID-19 vaccine regimensKlemis et al., Nature Communications (2022)

Brief Research Report: Anti-SARS-CoV-2 Immunity in Long Lasting Responders to Cancer Immunotherapy Through mRNA-Based COVID-19 VaccinationSistere-Oro et al., Frontiers in Immunology (2022)

Analysis of the humoral and cellular response after the third COVID-19 vaccination in patients with autoimmune hepatitisHartl et al., Liver International (2022) - PMID: 35840342

Respiratory mucosal immunity against SARS-CoV-2 following mRNA vaccination Tang et al., Science Immunology (202) - PMID: 35857583

Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies Minnar et al., Journal of Immunology (2022) - PMID: 35764364Product used: PepMix HPV 16 (E7)

Robust SARS-COV-2-specific T-cell immune memory persists long-term in immunocompetent individuals post BNT162b2 double shotPapadopoulou et al., Heliyon (2022) - PMID: 35815135Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)

A novel SARS-CoV-2 subunit vaccine engineered on an immune-activating platform technologyQuinlan et al., Human Vaccines & Immunotherapeutics (2022) - PMID: 35801956Product used: PepMix SARS-CoV-2 (Spike-RBD)

Safety and immunogenicity of intramuscular, single- dose V590 (rVSV-SARS-CoV-2 Vaccine) in healthy adults: Results from a phase 1 randomised, double- blind, placebo-controlled, dose-ranging trialRobbins et al., The Lancet (2022)Product used: PepMix SARS-CoV-2 (Spike Glycoprotein)

A Lymph Node Targeted Adjuvant and Engineered Subunit Vaccine Promotes Potent Immunity to Epstein-Barr Virus in HLA-expressing MiceDasari et al., Research Square (2022)Product used: PepMix EBV (GP350/GP340)

Longitudinal T Cell Responses against Ancestral, Delta, and Omicron SARS-CoV-2 Variants determined by Rapid Cytokine Release Assay in Whole BloodOliver et al., Immunohorizons (2022) - PMID: 35750357Products used: PepMix SARS-CoV-2 (Spike Glycoprotein SU1 & SU2), SARS-CoV-2 (Spike B.1.617/Delta), SARS-CoV-2 (Spike B.1.1.529 / BA.1 / Omicron)

Long-Lived Immunity in SARS-CoV-2-Recovered Children and Its Neutralizing Capacity Against OmicronSieber et al., Frontiers in Immunology (2022) - PMID: 35663948Product used: PepMix SARS-CoV-2 (VME1), SARS-CoV-2 (VEMP), SARS-CoV-2 (NCAP), SARS-CoV-2 (Spike B.1.1.529 / BA.1 / Omicron)

Natural Immunity against HIV-1: Progression of Understanding after Association StudiesMa Luo, Viruses (2022) Product used: PepMix HIV-1 (GAG) Ultra

In Vitro Generation of BK polyomavirus-specifc T cells for adoptive cell therapy in refractory cystitis hemorrhagic patients after hematopoietic stem cell transplantationNajafabadi et al., BMC Immunology (2022) - PMID: 35689183Product used: PepMix BKV (Capsid Protein VP1)

In Vitro Generation of BK polyomavirus-specifc T cells for adoptive cell therapy in refractory cystitis hemorrhagic patients after hematopoietic stem cell transplantation

Najafabadi et al., BMC Immunology (2022) - PMID: 35689183Product used:

T-cell proliferation assay for the detection of SARS-CoV-2-specific T-cellsChu et al., Clinical Chimica Acta (2022) - PMID: 35690083Products used: PepMix SARS-CoV-2 (Spike Glycoprotein), SARS-CoV-2 (NCAP), SARS-CoV-2 (VME1)

Pre-existing adaptive immunity to the RNA-editing enzyme Cas13d in humansTang et al., Nature Medicine (2022) - PMID: 35668177Product used: PepMix S. pyogenes (CAS9)_2 subpools

A DNA vaccine candidate delivered by an electroacupuncture machine provides protective immunity against SARS-CoV-2 infectionTzeng et al., Vaccines (2022)

Chimeric Virus-like Particle-Based COVID-19 Vaccine Confers Strong Protection against SARS-CoV-2 Viremia in K18-hACE2 MiceKaewborisuth et al., Vaccines (2022)

Cellular Immune Response after Vaccination with an Adjuvanted, Recombinant Zoster Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients Koldehoff et al., Vaccines (2022)

SARS-CoV-2 OmicronBA.1 variantbreakthrough infections in nursing home residentsafter an homologousthird dose of the Comirnaty® COVID-19 vaccine: Looking for correlates of protectionTorres et al., Journal of Medical Virology (2022) Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)

Durable immunogenicity, adaptation to emerging variants and low dose efficacy of AAV-based COVID19 platform in macaquesZabaleta et al., Molecular Therapy (2022)Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)

Enhanced Humoral Immune Response After COVID-19 Vaccination in Elderly Kidney Transplant Recipients on Everolimus Versus Mycophenolate Mofetil–containing Immunosuppressive Regimensde Boer et al., Translantation (2022) - PMID: 35546527Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)

SARS-CoV2 wild type and mutant specific humoral and T cell immunity is superior after vaccination than after natural infectionRichardson et al., PLoS One (2022) - PMID: 35468147Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein), SARS-CoV-2 (Spike B.1.1.7 / Alpha), SARS-CoV-2 (Spike B.1.351 / Beta), SARS-CoV-2 (Spike P.1 / Gamma), SARS-CoV-2 (Spike B.1.617.2 / Delta)

Two DNA vaccines protect against severe disease and pathology due to SARS-CoV-2 in Syrian hamsters Babuadze et al., NPJ Vaccines (2022) - PMID: 35474311Product used: PepMix™ SARS-CoV (Spike Glycoprotein)

Transcriptomic analysis reveals optimal cytokine combinations for SARS-CoV-2 Specific T cell therapy productsDurkee-Shock et al., Molecular Therapy: Methods & Clinical Development (2022)

Longitudinal T-Cell Responses After a Third SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis on Ocrelizumab or FingolimodCabeza et al., Neurology: Neuroimmunology & Neuroinflammation - PMID: 35523569Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)

Children and Adults With Mild COVID-19: Dynamics of the Memory T Cell Response up to 10 MonthsKaaijk et al., Frontiers in Immunology (2022) Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein), SARS-CoV-2 (NCAP), HCoV-OC43 (Spike Glycoprotein)

Strong peak immunogenicity but rapid antibody waning following third vaccine dose in elderlyresidents of care homesTut et al., Research Square (2022) Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)

Discordant antibody and T cell responses to the SARS-CoV-2 Omicron variant in COVID-19 mRNA vaccine recipientWoldemeskel et al., Clinical Infectious Diseases (2022) - PMID: 35438751Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein) & SARS-CoV-2 (S-RBD B.1.1.529 / Omicron)

USA SARS-CoV-2 Epsilon Variant: Though Highly Transmissible has an Adjusted Muted Host T-Cell ResponsePlummer et al., Clinical Infectious Diseases (2022) - PMID: 35438777Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein) & SARS-CoV-2 (Spike B.1.429 / Epsilon)

mRNA booster vaccination protects extremely aged mice against the SARS-CoV-2 Omicron variantDowling et al., Research Square (2022) Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein) & SARS-CoV-2 (S-RBD B.1.1.529 / Omicron)

Evaluation of overcoming Limited migration and Enhancing Cytomegalovirus-specific dendritic cell Vaccines with Adjuvant TEtanus pre-conditioning in patients with newlydiagnosed glioblastomaRandazzo et al., Clinical Trials (2022)Product used: PepMix™ CMVA (pp65)

Viral Evolution and Immunology of SARS-CoV-2 in a Persistent Infection after Treatment with Rituximabvan der Moerden et al., Viruses (2022)

Dynamics of SARS-CoV-2-Spike-reactive antibody and T-cell responses in chronic kidney disease patients within three months after COVID-19 full vaccinationPanizo et al., Clinical Kidney Journal (2022) Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)

Safety and immunogenicity of a reduced dose of the BNT162b2 mRNA COVID-19 vaccine (REDU-VAC): a single blind, randomized, non-inferiority trialPannus et al., MedRxiv (2022)

Safety and tolerability of AAV8 delivery of abroadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trialCasazza et al., Nature Medicine (2022) - PMID: 35411076 Product used: PepMix™ AAV8 (capsid protein)

NK cells limit therapeutic vaccine–induced CD8+ T cell immunity in a PD-L1–dependent mannerDiniz et al., Vaccines (2022) - PMID : 35417187

Temporal changes in T cell subsets and expansion of cytotoxic CD4+ T cells in the lungs in severe COVID-19Kaneko et al., Clinical Immunology (2022) - PMID: 35364330Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)

T cell response against SARS-CoV-2 persists after one year in patients surviving severe COVID-19Venet et al., EBioMedicine (2022) - PMID: 35349827Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein), SARS-CoV-2 (NCAP), SARS-CoV-2 (VME1)

CD4+ T Cell Dysfunction in Severe COVID-19 Disease is TNFalpha/TNFRI-DependentPopescu et al., American Journal of Respiratory Critical Care Medicine - PMID: 35348444Products used: PepMix™ SARS-CoV-2 (NCAP), SARS-CoV-2 (VEMP), SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)

The Quality of Anti-SARS-CoV-2 T Cell Responses Predicts the Neutralizing Antibody Titer in Convalescent Plasma DonorsKroemer et al., Front Public Health (2022) - PMID: 35372242Product used: PepMix™SARS-CoV-2 (Spike Glycoprotein), SARS-CoV-2 (NCAP), SARS-CoV-2 (VME1)

High antibody and reduced cellular response in children up to one year after SARS-CoV-2 infectionJacobsen et al., Research Square (2022) Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)

Immune responses against SARS-CoV-2 variants after two and three doses of vaccine in B-cell malignancies: UK PROSECO studyLim et al., Nature Cancer (2022) - PMID : 35332334Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)

Self-amplifying mRNA SARS-CoV-2 vaccines raise cross-reactive immune response to variants and prevent infection in animal modelsPalladino et al., Methods and Clinical Development (2022)Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein) & SARS-CoV-2 (NCAP)

Evolution of Humoral and Cellular Immunity in Two COVID-19 Breakthrough Infections After BNT162b2 VaccineGallais et al., Frontiers in Immunology (2022) - PMID: 35281046 Products used: PepMix™ SARS-CoV-2 (Spike B.1.1.7 / Alpha), SARS-CoV-2 (Spike B.1.351 / Beta), SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)

SARS‐CoV‐2 vaccination response in patients with autoimmune hepatitis and autoimmune cholestatic liver diseaseDuengelhoef et al., United European Gastroenterol Journal (2022) - PMID: 35289983 Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)

Novel T cell interferon gamma release assay (IGRA) using spike recombinant protein for COVID19 vaccine response and Nucleocapsid for SARS-Cov2 responseRenaudineau et al., Clinical Immunology (2022) - PMID: n.a.Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)

Immune response and safety of heterologous ChAdOx1-nCoV-19/mRNA-1273 vaccination compared with homologous ChAdOx1-nCoV-19 or homologous mRNA-1273 vaccinationSheng et al., Journal of the Formosan Medical Association (2022) - PMID: 35305895Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)

Modular capsid decoration boosts adenovirus vaccine-induced humoral and cellular immunity against SARS-CoV-2Dicks et al., BioRxiv (2022)Products used: PepMix™ SARS-CoV-2 (S-RBD), SARS-CoV-2 (Spike Glycoprotein)

SARS-CoV- 2 (COVID- 19)-specific T cell and B cell responses in convalescent rheumatoid arthritis: Monozygotic twins pair case observationArruda et al., Immunology (2022) - PMID: 35212005Products used: PepMix™ SARS-CoV-2 (NCAP) & SARS-CoV-2 (Spike Glycoprotein)

Humoral and Cellular Immune Responses of Solid Organ Transplant Patients on Belatacept to Three Doses of mRNA-Based Anti-SARS-CoV-2 VaccineAbravanel et al., Vaccines (2022) Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)

Three-month follow-up of heterologous vs homologous third vaccination in kidney transplant recipientsHeinzel et al., MedRxiv (2022)Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)

Limited Recognition of Highly Conserved Regions of SARS-CoV-2Swaminathan et al., Microbiology Spectrum (2022) - PMID: 35196796Products used: PepMix™ SARS-CoV-2 (Nsp12), SARS-CoV-2 (Spike Glycoprotein) & SARS-CoV-2 (NCAP)

Assessment of humora land cellular immune responses to SARSCoV-2 vaccination (BNT162b2) inimmunocompromised renal allograft recipientsZhang et al., Transplant Infectious Diseases (2022)Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)

Tacrolimus-resistant SARS-CoV-2-specific T-cell products to prevent and treat severe COVID-19 in immunosuppressed patientsPeter et al., Molecular Therapy (2022) Products used: PepMix™ SARS-CoV-2 (NCAP), SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2), SARS-CoV-2 (VEMP), SARS-CoV-2 (VME1), SARS-CoV-2 (AP3A), SARS-CoV-2 (NS7A), SARS-CoV-2 (NS7B), SARS-CoV-2 (ORF9B), SARS-CoV-2 (ORF10), SARS-CoV-2 (Spike B.1.1.7 / Alpha), SARS-CoV-2 (Spike B.1.351 / Beta), SARS-CoV-2 (Spike B.1.617.2 / Delta), SARS-CoV-2 (Spike B.1.1.529 / Omicron), CMVA (pp65)

Evaluation of IL-1β and IL-6 expression following EBNA-1 and BRLF-1 peptide treatment in Epstein Barr virus-positive multiple sclerosis patientsKianfar et al., Intervirology (2022)

Performance comparison of a fow cytometry immunoassay for intracellular cytokine staining and the QuantiFERON® SARS-CoV-2test for detection and quantifcation of SARS-CoV-2-Spike-reactiveIFN-γ-producing T cells after COVID-19 vaccinationTormo et al., European Journal of Clinical Microbiology & Infectious Diseases (2022) - PMID: 35165804Product used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)

SARS-CoV-2-specific T cells generated for adoptive immunotherapy are capable of recognizing multiple SARS-CoV-2 variantPanikkar et al., Pathogens (2022) - PMID: 35157735Products used: PepMix™ SARS-CoV-2 (AP3A), SARS-CoV-2 (NCAP), SARS-CoV-2 (VME1), SARS-CoV-2 (Spike Glycoprotein)

Polyfunctional pathogen-specific CD4+ T cells reside in the lungs and tumors of NSCLC patients Oja et al., BioRxiv (2022)Products used: PepMix™ HRSVB (Fusion Glycoprotein F0) & HRSVB (MSG)

T cell reactivity to the SARS-CoV-2 Omicron variant is preserved in most but not all prior infected and vaccinated individualsVivek Naranbhai et al., MedRxiv (2022) - PMID: 35018386 Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein), SARS-CoV-2 (NCAP), SARS-CoV-2 (VME1), SARS-CoV-2 (VEMP), SARS-CoV-2 (AP3A), SARS-CoV-2 (Spike B.1.617.2 / Delta)

Potent anti-viral activity of a trispecific HIV neutralizing antibody in SHIV-infected monkeysAmarendra Pegu et al., Cell Report (2022) - PMID: 34986348 Products used: PepMix™ HIV-1 (ENV) Ultra

Bystander CD4+ T cells infiltrate human tumors and are phenotypically distinctShamin Li et al., OncoImmunology (2022) - PMID: n.a.Products used: PepMix™ CMVA (pp65)

Innate and adaptive immune defects associated with lower SARS-CoV-2 BNT162b2 mRNA vaccine response in elderly peopleJoana Vitallé et al., medRxiv (2022) - PMID: n.a.Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)

Temporary hold of mycophenolate boosts SARS-CoV-2 vaccination-specific humoral and cellular immunity in kidney transplant recipients Eva Schrezenmeier et al., MedRxiv (2022) Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)

Dynamics of spike-and nucleocapsid specific immunity during long-term follow-up and vaccination of SARS-CoV-2 convalescentsNina Koerber et al., Nature Communications (2022)Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)

Persistent T-Cell Reactivity in a Seronegative Patient after SARS-CoV-2 Infection and One VaccinationNico Andreas et al., Vaccines (2022)Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)

Combination of ultrasound-based mechanical disruption of tumor with immune checkpoint blockade modifies tumor microenvironment and augments systemic antitumor immunityShinya Abe et al., Immunotherapy of Cancer (2022)Products used: PepMix™ HIV-1 (GAG) Ultra

Development of an effective immune response in adults with Down Syndrome 2 after SARS-CoV-2 vaccinationLaura Esparcia-Pinedo et al., MedRxiv (2022) Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2), SARS-CoV-2 (VME1), SARS-CoV-2 (NCAP), SARS-CoV-2 (Nsp5)

Wnt activation promotes memory T cell polyfunctionality via epigenetic regulator PRMT1Bo-Yi Sung et al., Journal of Clinical Investigation (2022) - PMID: 35040433 Products used: PepMix™ CMVA (pp65)

Clinical and Immunological Characteristics for BK Polyomavirus- associated Nephropathy after Kidney TransplantationTanaya Siripoon et al., Research Square (2022)Products used: PepMix™ BKV (capsid protein VP1), BKV (large T antigen)

T cell response to intact SARS-CoV-2 includes coronavirus cross-reactive and variant-specific componentsLichen Jing et al., MedRxiv et al., (2022)Products used: PepMix™ HCoV-OC43 (Spike Glycoprotein)

Persistently reduced humoral and cellular immune response following third SARS-CoV-2 mRNA vaccination in anti-CD20-treated multiple sclerosis patientsBajwa et al., MedRxiv (2022)

Antibody and T cell responses to SARS-CoV-2 mRNA vaccines during maintenance therapy for immune-mediated inflammatory diseasesDayam et al., MedRxiv (2022)

Infection or a third dose of mRNA vaccine elicit neutralizing antibody responses against SARS-CoV-2 in kidney transplant recipients Charmetant et al., Science Translational Medicine (2022) - PMID: 35103481 Products used: PepMix™ SARS-CoV-2 (NCAP), SARS-CoV-2 (Spike Glycoprotein), SARS-CoV-2 (VME1)

Concordance of B and T cell responses to SARS-CoV-2 infection, irrespective of symptoms suggestive of COVID-19Österdahl et al., MedRxiv (2022)

Differential localization and limited cytotoxic potential of duodenal CD8+ T cellsMvaya et al., JCI Insight (2022) - PMID: 35132966 Products used: PepMix™ HIV-1 (POL), HIV-1 (GAG) & HIV-1 (NEF)

Full efficacy and long-term immunogenicity induced by the SARS-CoV-2 vaccine candidate MVA-CoV2-S in miceLázaro-Frías et al., Vaccines (2022) Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)

mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits comparable B cell expansion, neutralizing antibodies and protection against OmicronGagne et al., BioRxiv (2022)Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein SUB1 & SUB2)

A Co-stimulatory CAR Improves TCR-based Cancer ImmunotherapyOmer et al., Cancer Immunology Research (2022) - PMID: 35176142Products used: PepMix™ EBV (EBNA1), EBV (LMP1), EBV (LMP2)

Effectiveness and durability of the mRNA vaccine-induced SARSCoV-2-specific humoral and cellular immunity in severe asthma patients on biological therapyProdrazil et al., MedRxiv (2022)Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein)

Impaired Anti-SARS-CoV-2 Humoral and Cellular Immune Response Induced by Pfizer-BioNTech BNT162b2 mRNA Vaccine in Solid Organ Transplanted PatientsMonica Miele et.al., American Journal of Transplantation (2021) - PMID: 34058052

CD8+ T Cells Specific for an Immunodominant SARS-CoV-2 Nucleocapsid Epitope Cross-React With Selective Seasonal CoronavirusesKatie E Lineburg et.al., Immunity (2021) - PMID: 33945786

Prime hAd5 Spike plus Nucleocapsid Vaccination Induces Ten-Fold Increases in Mean T-Cell Responses in Phase 1 Subjects that are Sustained Against Spike VariantsPete Sieling et.al., medRxiv (2021) - PMID: n.a.

Gene Transfer in Adeno-Associated Virus Seropositive Rhesus Macaques Following Rapamycin Treatment and Subcutaneous Delivery of AAV6, but Not Retargeted AAV6 VectorsStone et al., Human Gene Therapy (2021) - PMID: 32998579

Preclinical Evaluation of a SARS-CoV-2 mRNA Vaccine PTX-COVID19-BJun Liu et.al., bioRxiv (2021) - PMID: n.a.

A Lymph Node-Targeted Amphiphile Vaccine Induces Potent Cellular and Humoral Immunity to SARS-CoV-2Martin P Steinbuck et.al., Sci Adv. (2021) - PMID: 33446655

SARS-CoV-2 Spike Glycoprotein Vaccine Candidate NVX-CoV2373 Immunogenicity in Baboons and Protection in MiceJing-Hui Tian et.al., Nat Commun (2021) - PMID: 33446655

Safety and Immunogenicity of the SARS-CoV-2 BNT162b1 mRNA Vaccine in Younger and Older Chinese Adults: a Randomized, Placebo-Controlled, Double-Blind Phase 1 StudyJingxin Li et.al., Nat Med. (2021) - PMID: 33888900

BNT162b Vaccines Protect Rhesus Macaques From SARS-CoV-2Annette B Vogel et.al., Nature (2021) - PMID: 33524990

Older Adults Lack SARS CoV-2 Cross-Reactive T Lymphocytes Directed to Human Coronaviruses OC43 and NL63esGiulietta Saletti et.al., Sci Rep. (2021) - PMID: 33293664

SARS-CoV-2 Variants of Concern Partially Escape Humoral but not T-Cell Responses in COVID-19 Convalescent Donors and VaccineesDaryl Geers et.al., Sci Immunol. (2021) - PMID: 34035118

COVID-19 Immune Signatures Reveal Stable Antiviral T Cell Function Despite Declining Humoral ResponsesAgnes Bonifacius et.al., Immunity (2021) - PMID: 33567252

IL-33 Expression in Response to SARS-CoV-2 Correlates With Seropositivity in COVID-19 Convalescent IndividualsMichal A Stanczak et.al., Nat Commun. (2021) - PMID: 33837219

A Highly Specific Assay for the Detection of SARS-CoV-2-Reactive CD4 + and CD8 + T Cells in COVID-19 PatientsHenning Zelba et.al., J Immunol. (2021) - PMID: 33298615

SARS-CoV-2-Reactive T Cells in Healthy Donors and Patients With COVID-19Julian Braun et.al., Nature (2021) - PMID: 32726801

Functional Characterization of CD4+ T Cell Receptors Crossreactive for SARS-CoV-2 and Endemic CoronavirusesArbor G Dykema et.al., J Clin Invest. (2021) - PMID: 33830946

Culture Media Optimization for Chinese Hamster Ovary Cell Growth and Expression of Recombinant Varicella-Zoster Virus Glycoprotein EKwang Sung Kim et.al., Cytotechnology (2021) - PMID: 33897103

SARS-CoV-2 Protein Subunit Vaccination of Mice and Rhesus Macaques Elicits Potent and Durable Neutralizing Antibody ResponsesMarco Mandolesi et.al., Cell Reports Medicine (2021) - PMID: 33842900

SARS-CoV-2 mRNA Vaccine BNT162b2 Elicited a Robust Humoral and Cellular Response Against SARSCoV-2 VariantsDaniele Lilleri et.al., Research Square (2021) - PMID: n.a.

Children Develop Strong and Sustained Cross-Reactive Immune Responses Against Spike Protein Following SARS-CoV-2 Infection, With Enhanced Recognition of Variants of ConcernAlexander C. Dowell et.al., medRxiv (2021) - PMID: n.a.

Comorbid illnesses are associated with altered adaptive immune responses to SARS-CoV-2Krystle K.Q. Yu et.al., JCI Insight (2021) - PMID: 33621211

Targeting SARS-CoV-2 Receptor-Binding Domain to Cells Expressing CD40 Improves Protection to Infection in Convalescent MacaquesRomain Marlin et.al., Nature Communications (2021) - PMID: n.a.

Characterization of Recombinant Gorilla Adenovirus HPV Therapeutic Vaccine PRGN-2009Samuel T. Pellom et.al., JCI Insight (2021) - PMID: 33651712

Cytomegalovirus-Specific T-Cell Reconstitution Following Letermovir Prophylaxis after Hematopoietic Cell TransplantationDanniel Zamora et.al., In Press, Journal Pre-proof (2021) - PMID: 33657225

Optimization of Zika DNA Vaccine by Delivery SystemsYun Ha Lee et.al., Virology (2021) - PMID: 33780719

Human Cytomegalovirus and Epstein-Barr Virus Specific Immunity in Patients With Ulcerative ColitisRachele Ciccocioppo et.al., Clinical and Experimental Medicine (2021) - PMID: 33772380

Longitudinal Analysis of Human Memory T-Cell Response according to the Severity of Illness up to 8 Months after SARS-CoV-2 InfectionChang Kyung Kang et.al., The Journal of Infectious Diseases (2021) - PMID: 33755725

Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months following primary infectionJianmin Zuo et.al., Nature (2021) - PMID: 33674800

SARS-CoV-2 Spike Protein Arrested In The Closed State Induces Potent Neutralizing ResponsesGeorge W. Carnell et.al., bioRxiv (2021) - PMID: n.a.

First Report Demonstrating The Safety And Immunogenicity Of The SARS-COV-2 BNT162b1 mRNA Vaccine In Younger And Older Chinese Adults: A Randomized, Placebo-Controlled, Observer-Blind Phase I StudyFengcai Zhu et.al., Research Square (2021) - PMID: n.a.

Validation of an IFN-Gamma ELISpot Assay to Measure Cellular Immune Responses Against Viral Antigens in Non-Human PrimatesFan Yang et.al., Gene Ther. (2021) - PMID: 33432123

Poor Anti-SARS-CoV-2 Humoral and T-cell Responses After 2 Injections of mRNA Vaccine in Kidney Transplant Recipients Treated With BelataceptNathalie Chavator et al., Transplantation, (2021)

SARS-CoV-2 Specific Memory T Cell Epitopes Identified in COVID-19-Recovered SubjectsJuan Zhao et al., Virus Res, (2021)

Intrafamilial Exposure to SARS-CoV-2 Associated with Cellular Immune Response without Seroconversion, FranceFloriane Gallais et al., Emerg Infect Dis, (2021)

SARS-CoV2 Mutant-Specific T Cells and Neutralizing Antibodies After Vaccination and up to 1 Year After InfectionRichardson, J.R. et al., ISAR Bioscience, (2021)

COVID-19 Subunit Vaccine with a Combination of TLR1/2 and TLR3 Agonists Induces Robust and Protective ImmunitySoo-Kyung Jeong et al., Vaccines, (2021)

M2-Deficient Single-Replication Influenza Vaccine–Induced Immune Responses Associated With Protection Against Human Challenge With Highly Drifted H3N2 Influenza StrainJoseph Eiden et al., J Infect Dis, (2021)

Impairment of CD4+ T and Memory B Cell Responses but Normal Memory CD8+T-Cell Activation on Crohn’s Disease after COVID-19 Vaccination: A Twin CaseFabiana Gil-Melgaço et al., Viruses, (2021)

Weak Immunogenicity of SARS-CoV-2 Vaccine in Patients With Hematologic MalignanciesFlorent Malard et al., Blood Cancer J, (2021)

CD4+ T Cells of Prostate Cancer Patients Have Decreased Immune Responses to Antigens Derived From SARS-CoV-2 SpikePavla Taborska et al., Front Immunol, (2021)

T Cell–Mediated Response to SARS-CoV-2 in Liver Transplant Recipients With Prior COVID-19Mario Fernández-Ruiz et al., Am J Transplant, (2021)

Prospective Assessment of SARS-CoV-2 Seroconversion (PASS) Study: an Observational Cohort Study of SARS-CoV-2 Infection and Vaccination in Healthcare WorkersJackson, B.M. et al., BMC Infect Dis, (2021)

Cellular Immunity Predominates Over Humoral Immunity After Homologous and Heterologous mRNA and Vector-Based COVID-19 Vaccine Regimens in Solid Organ Transplant RecipientsTina Schmidt et al., Am J Translplant, (2021)

The Legacy of Maternal SARS-CoV-2 Infection on the Immunology of the NeonateSarah Gee et al., Nat Immunol, (2021)

A Single-Cycle Influenza A Virus-Based SARS-CoV-2 Vaccine Elicits Potent Immune Responses in a Mouse ModelSurapong Koonpaew et al., Vaccines, (2021)

Impact of Multiple Sclerosis Disease-Modifying Therapies on SARS-CoV-2 Vaccine-Induced Antibody and T Cell ImmunitySabatino, J.J. et al., MedRxiv, (2021)

Complete Protection of Nasal and Lung Airways Against SARS-CoV-2 Challenge by Antibody Plus Th1 Dominant N- and S-Specific T-Cell Responses to Subcutaneous Prime and Thermally-Stable Oral Boost Bivalent hAd5 Vaccination in an NHP StudyElizabeth Gabitzsch et al., BioRxiv, (2021)

Cytomegalovirus-Specific Immunity Recovers More Slowly after Cord Blood Transplantation Compared with Matched Sibling Donor Allogeneic TransplantationBejanyan, J. et al., Transplant Cell Ther, (2021)

The Evaluation of Novel Oral Vaccines Based on Self-Amplifying RNA Lipid Nanparticles (saRNA LNPs), saRNA Transfected Lactobacillus Plantarum LNPs, and saRNA Transfected Lactobacillus Plantarum to Neutralize SARS-CoV-2 Variants Alpha and DeltaReza Keikha et al., Sci Rep, (2021)

Single-Dose Intranasal Administration of AdCOVID Elicits Systemic and Mucosal Immunity against SARS-CoV-2 and Fully Protects Mice from Lethal ChallengeKing R.G. et al., Vaccines, (2021)

T-Cell and Antibody Immunity After COVID-19 mRNA Vaccines in Healthy and Immunocompromised Subjects-An Exploratory StudyRakesh Sindhi et al., MedRxiv, (2021)

SARS-CoV-2-Specific Antibody and T Cell Response Kinetics According to Symptom SeverityJi Yeun Kim et al., Am J Trop Med Hyg, (2021)

Implementation of Adenovirus-Mediated Pulmonary Expression of Human ACE2 in HLA Transgenic Mice Enables Establishment of a COVID-19 Murine Model for Assessment of Immune Responses to SARS-CoV-2 InfectionTheodor Chitlaru et al., Pathogens, (2021)

Safety and Immunogenicity of an Inactivated Recombinant Newcastle Disease Virus Vaccine Expressing SARS-CoV-2 Spike: Interim Results of a Randomised, Placebo-Controlled, Phase 1/2 TrialPunnee Pitisuttihum et al., MedRxiv, (2021)

Protracted yet Coordinated Differentiation of Long-Lived SARS-CoV-2-Specific CD8+ T Cells During COVID-19 ConvalescenceTongcui Ma et al., BioRxiv, (2021)

SARS-Cov-2 Spike Protein Fragment 674–685 Protects Mitochondria From Releasing Cytochrome c in Response to Apoptogenic InfluenceOlena Kalashnyk et al., Biochem Biophys Res Commun, (2021)

CD8+PD-L1+CXCR3+ Polyfunctional T Cell Abundances Are Associated With Survival in Critical SARS-CoV-2–Infected PatientsLucille Adam et al., JCI Insight, (2021)

Protective Antibodies Elicited by SARS-CoV-2 Spike Protein Vaccination are Boosted in the Lung After Challenge in Nonhuman PrimatesJoseph R. Francica et al., Sci Transl Med, (2021)

Profiling SARS-CoV-2 HLA-I Peptidome Reveals T Cell Epitopes From Out-of-Frame ORFsShira Weingarten-Gabbay et al., Cell, (2021)

A Short Corticosteroid Course Reduces Symptoms and Immunological Alterations Underlying Long-COVIDAlberto Utrero-Rico et al., Biomedicines, (2021)

COVID-19 Vaccine mRNA-1273 Elicits a Protective Immune Profile in Mice That is not Associated With Vaccine-Enhanced Disease Upon SARS-CoV-2 ChallengeDiPiazza, A.T. et al., Immunity, (2021)

Polymeric and Lipid Nanoparticles for Delivery of Self-Amplifying RNA VaccinesBlakney, A.K. et al., J Control Release, (2021)

An Enveloped Virus-Like Particle Vaccine Expressing a Stabilized Prefusion form of the SARS-CoV-2 spike Protein Elicits Highly Potent ImmunityAnne-Catherine Fluckiger et al., Vaccine, (2021)

Intranasal Plus Subcutaneous Prime Vaccination With a Dual Antigen COVID-19 Vaccine Elicits T-Cell and Antibody Responses in MiceAdrian Rice et al., Sci Rep, (2021)

Change in Symptoms and Immune Response in People with Post-Acute Sequelae of SARS-Cov-2 Infection (PASC) After SARS-Cov-2 VaccinationDaisy Massay et al., MedRxiv, (2021)

Evolution of SARS-CoV-2 Immune Responses in Nursing Home Residents Following Full Dose of the Comirnaty® COVID-19 VaccineGiménez, E. et al., J Infect (2021)

Correlates of Neutralization against SARS-CoV-2 Variants of Concern by Early Pandemic SeraVidal, S-J. et al., J Virol, (2021)

Application of Spectral Library Prediction for Parallel Reaction Monitoring of Viral PeptidesGrossegesse, M. et al., Proteomics, (2021)

Preserved T-cell Response in anti-CD20 Treated Multiple Sclerosis Patients Following SARS-CoV-2 VaccinationSimon Faissner et al., Res Square, (2021)

Durable T cell responses contrast with faster antibody waning in BNT162b2-vaccinated elderly at 6 monthLaurent Renia et al., Res Square, (2021)

SARS-CoV-2 ferritin nanoparticle vaccine induces robust innate immune activity driving polyfunctional spike-specific T cell responsesJoshua M. Carmen et al., Vaccines, (2021)

mRNA Vaccine Protects against Zika VirusLex G. Medina-Magües et al., Vaccines, (2021)

A SARS-CoV-2 ferritin nanoparticle vaccine elicits protective immune responses in nonhuman primatesM. Gordon Joyce et al., Science Translational Medicine

SARS-CoV-2-Specific Cell-Mediated Immunity in Kidney Transplant Recipients Recovered From COVID-19Mario Fernández-Ruiz et al., Transplantation, (2021)

First-in-Human Phase I Clinical Trial of an SFV-Based RNA Replicon Cancer Vaccine against HPV-Induced CancersFenne L. Komdeur et al., Mol Ther, (2021)

SARS-CoV-2 Vaccination in Rituximab-Treated Patients: B Cells Promote Humoral Immune Responses in the Presence of T-Cell-Mediated ImmunityDaniel Mrak et al., Ann Rheum Dis, (2021)

Comorbid Illnesses are Associated With Altered Adaptive Immune Responses to SARS-CoV-2Krystle Kq Yu et al., JCI Insight, (2021)

Longitudinal Analysis of Human Memory T-Cell Response According to the Severity of Illness up to 8 Months After Severe Acute Respiratory Syndrome Coronavirus 2 InfectionChang Kyung Kang et al., J Infect Dis, (2021)

Deconvoluting the T Cell Response to SARS-CoV-2: Specificity Versus Chance and Cognate Cross-ReactivityAlexander A. Lehmann et al., Front Immunology, (2021)

Identification of Conserved SARS-CoV-2 Spike Epitopes That Expand Public cTfh Clonotypes in Mild COVID-19 PatientsXiuyuan Lu et al., J Exp Med, (2021)

Cytomegalovirus Specific Polyfunctional T-Cell Responses Expressing CD107a Predict control of CMV Infection After Liver TransplantationÂngela Carvalho-Gomes et al., Cellular Immunology, (2021)

Off the Shelf Third Party Virus Specific T-Cell Therapy to Treat JC Polyomavirus Infection in Hematopoietic Stem Cell Transplant RecipientsJeremy D. Rubinstein et al., Transplant Cell Ther, (2021)

Effectiveness of ChAdOx1 nCoV-19 Vaccine Against SARS-CoV-2 Infection During the Delta (B.1.617.2) Variant Surge in India: a Test-Negative, Case-Control Study and a Mechanistic Study of Post-Vaccination Immune ResponsesRamachandran Thiruvengadam et al., Lancet Infect Dis, (2021)

Rituximab impairs B-cell response but not T-cell response to COVID-19 vaccine in auto-immune diseasesSamuel Bitoun et al., Arthritis & Rheumatology, (2021)

Latent CMV Infection Is Associated With Lower Influenza Virus-Specific Memory T-Cell Frequencies, but Not With an Impaired T-Cell Response to Acute Influenza Virus InfectionSarah P.H. van den Berg et al., Front Immunology, (2021)

Rituximab impairs B-cell response but not T-cell response to COVID-19 vaccine in auto-immune diseasesSamuel Bitoun et al., Arthritis & Rheumatology (2021) - PMID: 34962357

Latent CMV Infection Is Associated With Lower Influenza Virus-Specific Memory T-Cell Frequencies, but Not With an Impaired T-Cell Response to Acute Influenza Virus InfectionSara P H van den Berg et al., Front Immunology (2021) - PMID: 34025665

CMV-Specific Immunity Recovers Slowly after Cord Blood Compared with Matched Sibling Donor Allogeneic TransplantationN.Bejanyan et.al., Transplantation and Cellular Therapy (2020) - PMID: n.a.

Human Cytomegalovirus-Encoded microRNAs Can Be Found in Saliva Samples from Renal Transplant RecipientsShelley Waters et.al., Noncoding RNA. (2020) - PMID: 33353107

Persistent Cellular Immunity to SARS-CoV-2 InfectionGaëlle Breton et.al., bioRxiv (2020) - PMID: 33330867

Adaptive Immune Responses to SARS-CoV-2 in Recovered Severe COVID-19 PatientsBeatriz Olea et.al., medRxiv (2020) - PMID: n.a.

1IL-2 and IFN-γ are Biomarkers of SARS-CoV-2 Specific Cellular Response in Whole Blood Stimulation AssaysBegoña Pérez-Cabezas et.al., medRxiv (2020) - PMID: n.a.

BNT162b2 Induces SARS-CoV-2-Neutralising Antibodies and T Cells in HumansUgur Sahin et.al., medRxiv (2020) - PMID: n.a.

Deconvoluting the T Cell Response to SARS-CoV-2: Specificity Versus Chance- and Cognate Cross-ReactivityAlexander A. Lehmann et.al., bioRxiv (2020) - PMID: n.a.

Guidelines For Analysis of Low-Frequency Antigen-Specific T Cell Results: Dye-Based Proliferation Assay vs 3H-Thymidine IncorporationDaniela Di Blasi et.al., Journal of Immunological Methods (2020) - PMID: 33152332

Antigenic Competition in the Generation of Multi-Virus-Specific Cell Lines for Immunotherapy of Human Cytomegalovirus, Polyomavirus BK, Epstein-Barr Virus and Adenovirus Infection in Haematopoietic Stem Cell Transplant RecipientsKateřina Roubalová et.al., Immunol Lett. (2020) - PMID: 33031870

Convalescent Plasma Therapy for B-Cell Depleted Patients With Protracted COVID-19 DiseaseThomas Hueso et.al., Blood (2020) - PMID: 32959052

mRNA Based SARS-CoV-2 Vaccine Candidate CVnCoV Induces High Levels of Virus Neutralizing Antibodies and Mediates Protection in RodentsSusanne Rauch et.al., bioRxiv (2020) - PMID: n.a.

Functional Immune Monitoring of BK Virus And Donor‐Specific T‐cell Effector Immune Responses to Guide Treatment Decision‐Making After Kidney Transplantation; an Illustrative Case Report And Literature ReviewMarta Lepore et.al., Transplant Infectious Disease (2020) - PMID: 33070461

Divergent SARS‐CoV‐2‐Specific T and B Cell Responses in Severe but Not Mild COVID‐19 PatientsAnna E. Oja et.al., European Journal of Immunology (2020) - PMID: 33073359

Characteristicsof Rapamycin-Treated T Cell Products for Advanced Adoptive T Cell Therapy and Evaluation of Clinical FeasibilityLeila Amini et.al., Dissertation (2020) - PMID: n.a.

Intrafamilial Exposure to SARS-CoV-2 Induces Cellular Immune Response without SeroconversionGallais F. et.al., Emerg Infect Dis (2020) - PMID: n.a.

T Cell and Antibody Responses to SARS-CoV-2: Experience From a French Transplantation and Hemodialysis Center During the COVID-19 PandemicCandon S. et.al., Am J Transplant (2020) - PMID: n.a.

Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older AdultsEvan J. Anderson et.al., New England Journal of Medicine (2020) - PMID: 32991794

Single-Shot Ad26 Vaccine Protects Against SARS-CoV-2 in Rhesus MacaquesMercado et.al., Nature (2020) - PMID: 32731257

Evaluation of the mRNA-1273 Vaccine Against SARS-CoV-2 in Nonhuman PrimatesCorbett et.al., N Engl J Med (2020) - PMID: 32722908

Divergent SARS-CoV-2-Specific T and B Cell Responses in Severe but not Mild COVID-19Oja et.al., bioRxiv (2020) - PMID: n.a.

Self-Amplifying RNA SARS-CoV-2 Lipid Nanoparticle Vaccine Candidate Induces High Neutralizing Antibody Titers in MiceMcKay et.al., Nature (2020) - PMID: 32647131

Generation of SARS-CoV-2 S1 Spike Glycoprotein Putative Antigenic Epitopes in Vitro by Intracellular AminopeptidasesStamatakis et.al., bioRxiv (2020) - PMID: n.a.

SARS-CoV-2-Specific T Cells Exhibit Unique Features Characterized by Robust Helper Function, Lack of Terminal Differentiation, and High Proliferative PotentialNeidleman et.al., bioRxiv (2020) - PMID: 32577663

A Longitudinal Study of Immune Cells in Severe COVID-19 PatientsPayen et.al., medRXiv (2020) - PMID: n.a.

SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen PreparednessCorbett et.al., bioRxiv (2020) - PMID: 32577634

Presence of SARS-CoV-2 Reactive T Cells in COVID-19 Patients and Healthy DonorsBraun et.al., Nature (2020) - PMID: 32726801

SARS‐CoV‐2‐Reactive Interferon‐γ‐Producing CD8+ T Cells in Patients Hospitalized with Coronavirus Disease 2019Estela Giménez et.al., Journal of Medical Virology (2020) - PMID: 32579268

Evaluation of T-Activated Proteins as Recall Antigens to Monitor Epstein–Barr Virus and Human Cytomegalovirus-Specific T Cells in a Clinical Trial SettingNina Körber et.al., Journal of Translational Medicine (2020) - PMID: 32552697

Modified Alphavirus-Vesiculovirus Hybrid VaccineVectors for Homologous Prime-Boost Immunotherapyof Chronic Hepatitis BCarolina Chiale et.al., Vaccines (2020) - PMID: 32517032

Duration of Cellular and Humoral Responses After Quadrivalent Human Papillomavirus Vaccination in Healthy Female Adultswith or Without Prior Type 16 and/or 18 ExposureLilin Lai et.al., Vaccines (2020) - PMID: n.a.

A SARS-CoV-2 mRNA Vaccine — Preliminary ReportLisa A Jackson et.al., N Engl J Med (2020) - PMID: 32663912

HBV‐Specific CD8 T Cells Present Higher TNFα Expression But Lower Cytotoxicity in Hepatocellular CarcinomaLudong Zhao et.al., Clinical & Experimental Immunology (2020) - PMID: 32474905

Safety and Immunogenicity of a Zika Purified Inactivated Virus Vaccine Given Via Standard, Accelerated, or Shortened Schedules: a Single-Centre, Double-Blind, Sequential-Group, Randomised, Placebo-Controlled, Phase 1 TrialKathryn E Stephenson et.al., The Lancet Infectious Diseases (2020) - PMID: n.a.

Assessing Anti-HCMV Cell Mediated Immune Responses in Transplant Recipients and Healthy Controls Using a Novel Functional AssayCharlotte J. Houldcroft et.al., Cell-Mediated Immunity to HCMV (2020) - PMID: n.a.

Evaluation of Glycoprotein E Subunit And Live Attenuatedvaricella‐Zoster Virus Vaccines Formulated With Asingle‐Strand RNA‐Based AdjuvantSu Jeen Lee et.al., Immunity, Inflammation and Disease (2020) - PMID: 32167678

Women Who Received Varicella Vaccine Versus Natural Infection Have Different Long-Term T Cell Immunity but Similar Antibody LevelsEllen Tourtelot et.al., Vaccine (2020) - PMID: 31959424

TGF‐β Promotes The Function Of HIV‐Specific CXCR5+CD8 T CellsHong-Ge Yang et.al., Microbiology and Immunology (2020) - PMID: 32221997

Persistent Expansion And Th1-Like Skewing of HIV-Specific Circulating T Follicular Helper Cells During Antiretroviral TherapyJulia Niessl Wu et.al., EBioMedicine (2020) - PMID: 32268275

Preserved Specific Anti-Viral T-Cell Response But Associated With Decreased Lupus Activity In SLE Patients With Cytomegalovirus InfectionChien-Sheng Wu et.al., British Society for Rheumatology (2020) - PMID: 32306043

A Chimeric Yellow Fever-Zika Virus Vaccinecandidate Fully Protects Against Yellow Fever Virusinfection in MiceDieudonné Buh Kum et.al., Emerging Microbes & Infections (2020) - PMID: 32116148

Efficacy, Immunogenicity, and Safety of an Oral Influenza Vaccine: a Placebo-Controlled And Active-Controlled Phase 2 Human Challenge StudyDavid Liebowitz et.al., The Lancet Infectious Diseases (2020) - PMID: 31978354

Immunogenicity of Novel mRNA COVID-19 Vaccine MRT5500 in Mice and 2 Non-Human PrimatesKirill V. Kalnin et.al., Cancer Discovery (2019) - PMID: n.a.

Tracking Dye‐Independent Approach to Identify and Isolate In Vitro Expanded T CellsGeorge Elias et.al., Journal of Quantitative Cell Science (2019) - PMID: 31356002

Adenovirus Vector-Based Vaccines Confer Maternal-Fetal Protection against Zika Virus Challenge in Pregnant IFN-αβR−/− MiceRafael A.Larocca et.al., Clinical and Translational Report (2019) - PMID: 31668877

Tumor-Infiltrating B Cells Affect the Progression of Oropharyngeal Squamous Cell Carcinoma Via Cell-To-Cell Interactions With CD8+ T CellsKamila Hladikova et.al., Journal for ImmunoTherapy of Cancer (2019) - PMID: 31623665

PD-1 Blockade and TLR7 Activationlack Therapeutic Benefit in Chronic SIV-Infected Macaqueson Antiretroviral TherapyElena Bekerman et.al., Antimicrob. Agents Chemother. (2019) - PMID: 31501143

Deciphering Effects of Uncontrolled Cytomegalovirus Replication on Immune Responses in Cytomegalovirus DNA-Positive Renal Transplant RecipientsNandini Makwana et.al., Viral Immunology (2019) - PMID: 31536468

Generation of HPV-Specific T-CellsCarlos A. Ramos et.al., United States Patent Application 20190224302 (2019) - PMID: n.a.

A Vaccine Based on Recombinant Modified Vaccinia Ankara Containing the Nucleoprotein from Lassa Virus Protects Against Disease Progression in a Guinea Pig ModelE.M.Kennedy et.al., Vaccine (2019) - PMID: 31331770

A Novel Simplified Method of Generating Cytomegalovirus-Specific Cytokine-Induced Killer Cells of High Specificity and Superior Potency with GMP ComplianceYen Hoon Luah et.al., Clinical Immunology (2019) - PMID: 31229666

Generation of Zika Virus–Specific T Cells from Seropositive and Virus-Naïve Donors for Potential Use as an Autologous or “Off-the-Shelf” ImmunotherapeuticRyo Hanajiri et.al., Cytotherapy (2019) - PMID: n.a.

HBeAg Seroconversion is Associated with a More Effective PD-L1 Blockade During Chronic Hepatitis B InfectionSara Ferrando-Martinez et.al., JHEP Reports (2019) - PMID: n.a.

Enhancement of Immune Responses by Guanosine-Based Particles in DNA Plasmid Formulations against Infectious DiseasesSaritza Santos et.al., Journal of Immunology Research (2019) - PMID: n.a.

Prospective Assessment of CMV Immunity in High-Risk Donor Seropositive (D+) Recipient Seronegative (R-) Liver Transplant Recipients Receiving Either Preemptive Therapy or ProphylaxisAjit P Limaye et.al. ,The Journal of Infectious Diseases (2019) - PMID: n.a.

Phenotypic and Functional Differences Between HHV-6 and HCMV Specific T-CellsSolène Fastenackels et.al. , Journal of Virology (2019) - PMID: 30996090

Evaluation of EBV- and HCMV-Specific T Cell Responses in Systemic Lupus Erythematosus (SLE) Patients Using a Normalized Enzyme-Linked Immunospot (ELISPOT) AssayIrene Cassaniti et.al. , PLoS Pathogens (2019) - PMID: n.a.

T-Cell Responses Targeting HIV Nef Uniquely Correlate With Infected Cell Frequencies After Long-Term Antiretroviral TherapyAllison S. Thomas et.al. , PLoS Pathogens (2019) - PMID: 28931091

Measurement of CD8.sup.+ and CD4.sup.+ T Cell Frequencies Specific for EBV LMP1 and LMP2a Using mRNA-Transfected DCsDae-Hee Sohn et.al. , PLoS ONE (2019) - PMID: 26023769

Efficient Induction of Cell-Mediated Immunity to Varicella-Zoster Virus Glycoprotein E Co-Lyophilized with a Cationic Liposome-Based Adjuvant in MiceSeo Ri Wui et.al. , Vaccine (2019) - PMID: 30827737

Penalized Supervised Star Plots: Example Application in Influenza-Specific CD4+ T CellsTyson H. Holmes et.al. , Viral Immunology (2019) - PMID: 30698511

Antigen-Specific TCR Signatures of Cytomegalovirus InfectionAlina Huth et.al. , The Journal of Immunology (2018) - PMID: 30587531

Developmental Induction of Human T-cell Responses Against Candida Albicans and Aspergillus FumigatusKatrin Vogel et.al. , Scientific Reportsvolume (2018) - PMID: 30442915

Activation of Resident Memory T Cells for Cancer ImmunotherapyMasopust Jr et.al. , United States Patent Application 20180325952 (2018) - PMID: n.a.

Epstein-Barr Virus (EBV)-derived BARF1 Encodes CD4-and CD8-restricted Epitopes as Targets for T-cell ImmunotherapyM Kalra et.al. , Cytotherapy (2018) - PMID: 30396848

Generating HPV Antigen-specific Cells from a Native T Cell PopulationCM Bollard et.al. , US Patent App. 15/771,648, 2018 (2018) - PMID: n.a.

Method For Preparing Genetically-Modified T Cells Which Express Chimeric Antigen ReceptorNishio et.al. , United States Patent Application 20180289742 (2018) - PMID: n.a.

PI HighlightLL Kelley , PACT Newsletter (2018) - PMID: n.a.

Replication Deficient Human Adenovirus Vector Serotype 19a/64: Immunogenicity in Mice and Female Cynomolgus MacaquesRagonnaud et al., Vaccine (2018) - PMID: 30190120

Establishment and Operation of a Third Party Virus-Specific T-Cell Bank Within an Allogeneic Stem Cell Transplant ProgramWithers et al., Biology of Blood and Marrow Transplantation (2018) - PMID: 30172015

Humoral and Cellular Immunity to RSV in Infants, Children and AdultsGreen et al., Vaccine (2018) - PMID: 30177258

Altered CD4+ T‐Cell Immunity in Nurses Occupationally Exposed to Viral PathogensElias et al., Clin Exp Immunol (2018) - PMID: 30076783

Dynamics of Virus‐Specific T Cell Immunity in Pediatric Liver Transplant RecipientsArasaratnam et al., American Journal of Transplantation (2018) - PMID: 29900673

Pepmixes To Generate Multiviral Ctls With Broad SpecificityLeen et al., US Patent App. 15/905,176, (2018) - PMID: n.a.

Deleterious Effect of Steroids on Cytomegalovirus Infection Rate after Allogeneic Stem Cell Transplantation Depends on Pretransplant Cytomegalovirus Serostatus of Donors and RecipientsSuárez-Lledó et al., Biology of Blood and Marrow Transplantation (2018) - PMID: 29753162

Antiviral T Cells for Adenovirus in the Pretransplant Period: A Bridge Therapy for Severe Combined ImmunodeficiencyMiller et al., Biology of Blood and Marrow Transplantation (2018) - PMID: 29753156

Employment of the Human Thymus as an Alternative Source of Regulatory T-Cells to Develop an Immunotherapy to Prevent Rejection in Transplanted ChildrenBernaldo de Quirós et al., Cytotherapy (2018) - PMID: n.a.

Production of Quadrivalent Virus-Specific T Cells Utilizing Peptide StimulationA. Damen et al., Cytotherapy (2018) - PMID: n.a.

An Antigen-Free, Plasmacytoid Dendritic Cell–Targeting Immunotherapy To Bolster Memory CD8+ T Cells in Nonhuman PrimatesMasuta et al., J Immunol. (2018) - PMID: 29431693

Multi-Antigenic Human Cytomegalovirus mRNA Vaccines that Elicit Potent Humoral and Cell-Mediated ImmunityJohn et al., Sci Rep. (2018) - PMID: 29456015

Cytomegalovirus-Specific T-Cells Are Associated with Immune Senescence, But Not With Systemic Inflammation, in People Living with HIVBallegaard et al., Sci Rep. (2018) - PMID: 29491459

Toward a Rapid Production of Multivirus-Specific T Cells Targeting BKV, Adenovirus, CMV, and EBV from Umbilical Cord BloodCorrales et al., Mol Ther Methods Clin Dev. (2017) - PMID: 28480300

IL28B Genetic Variation and Cytomegalovirus-Specific T-cell Immunity in Allogeneic Stem Cell Transplant Recipients.Corrales et al., Journal of Medical Virology (2015) - PMID: 27591738

Mycobacteria-Specific Cytokine Responses Detect TB Infection and Distinguish Latent from Active TBTebruegge et al., Am J Respir Crit Care Med. (2015) - PMID: 26030187

Method for Preparing Antigen-Specific Cytotoxic T-Cells by Using Activated B-Cells and use ThereofKang et al., United States Patent Application 20180023054 (2018) - PMID: n.a.

Production of Trivalent Antigen-Specific T Cells Utilizing Viral Peptide StimulationHeyenbruch et al., Biology of Blood and Marrow Transplantation (2018) - PMID: n.a.

Differential Expression of CD8+ T Cell Cytotoxic Effector Molecules in Blood and Gastrointestinal Mucosa in HIV-1 InfectionKiniry et al., The Journal of Immunology (2018) - PMID: 29352005

"Cytomegalovirus (CMV) Immune Monitoring with ELISPOT and QuantiFERON-CMV Assay in Seropositive Kidney Transplant Recipients"Lee et al., Plos One (2017) - PMID: 29232714

Asian Elephant T Cell Responses to Elephant Endotheliotropic Herpesvirus (EEHV)Fuery et al., Journal of Virology (2017) - PMID: 29263271

Follistatin-Like Protein-1 Upregulates Dendritic Cell-Based Immunity in Patients with Nasopharyngeal CarcinomaWang Hong et al., Journal of Interferon & Cytokine Research (2017) - PMID: 29135371

Methods of Cell Culture for Adoptive Cell TherapyVera et al., US Patent 20,170,267,973, 2017 (2017) - PMID: n.a.

The Effect of Genetic Variants Affecting NK Cell Function on Cardiovascular Health and the Burden on CMVWaters et al., Hum Immunol. (2017) - PMID: 28987961

Protein Structure Shapes Immunodominance in the CD4 T cell Response to Yellow Fever VaccinationKoblischke et al., Sci Rep. (2017) - PMID: 28827760

Immunologic Profiling of Human Metapneumovirus (hMPV) Towards the Development of a Targeted ImmunotherapyTzannou et al., The Journal of Infectious Diseases (2017) - PMID: n.a

Safety and Immunogenicity of a mRNA Rabies Vaccine in Healthy Adults: an Open-label, Non-randomised, Prospective, First-in-human Phase 1 Clinical TrialAlberer et al., Lancet. (2017) - PMID: 28754494

Vorinostat Renders the Replication-Competent Latent Reservoir of Human Immunodeficiency Virus (HIV) Vulnerable to Clearance by CD8 T CellsSung et al., EBioMedicine (2017) - PMID: 28803740

CpG Oligonucleotides Increase HBV-Specific Cytokine Responses in Whole Blood and Enhance Cytokine Release Assay SensitivityDammermann et al., J Virol Methods (2017) - PMID: 28739303

Elucidating CD8+ T-Cell Responses in the Rectal Mucosa During HIV InfectionKiniry et al., ProQuest (2017) - PMID: n.a.

Vaccination with a Codon-Optimized A27L-Containing Plasmid Decreases Virus Replication and Dissemination After Vaccinia Virus ChallengeMartínez et al., Vaccine (2017) - PMID: 28629922

Pre-Transplant Immune Factors May be Associated with BK Polyomavirus Reactivation in Kidney Transplant RecipientsDeWolfe et al., Plos one (2017) - PMID: 28562595

Decitabine Treatment Sensitizes Tumor Cells to T-Cell-Mediated Cytotoxicity in Patients with Myelodysplastic SyndromesZheng Zhang et al., Am J Transl Res (2017) - PMID: 28337274

An Early Immediate Early Protein IE-1–Specific T-Cell Polyfunctionality Is Associated With a Better Control of Cytomegalovirus Reactivation in Kidney TransplantationDekeyser et al., Kidney International Reports (2017) - PMID: n.a.

Development of a Replication-Deficient Adenoviral Vector-Based Vaccine Candidate for the Interception of HPV16- and HPV18-Induced Infections and DiseaseKhan et al., International Jounal of Cancer (2017) - PMID: 28263390

Breadth of T Cell Responses after Immunization with Adenovirus Vectors Encoding Ancestral Antigens or Polyvalent Papillomavirus AntigensRagonnaud et al., Scandinavian Journal of Immunology (2017) - PMID: 28109028

Primary Cytomegalovirus Infection in Seronegative Kidney Transplant Patients Is Associated with Protracted Cold Ischemic Time of Seropositive Donor OrgansSchlott et al., Plos One (2017) - PMID: 28129395

Perturbed CD8+ T Cell TIGIT/CD226/PVR Axis Despite Early Initiation of Antiretroviral Treatment in HIV Infected IndividualsTauriainen et al., Scientific Reports (2017) - PMID: 28084312

Development of Novel Replication-defective Lymphocytic Choriomeningitis Virus Vectors Expressing SIV AntigensMacMaster et al., Vaccine (2016) - PMID: 27899229

T Cells Infiltrating Diseased Liver Express Ligands for the NKG2D Stress Surveillance SystemHuang et al., Journal of Immunology (2016) - PMID: 28031333

Polynucleotides For Treating Oncogenic Viral Polypeptide Positive TumorsLee et al., US Patent 20,160,376,324 (2016) - PMID: n.a.

Therapeutic Vaccine Targeting Epstein-Barr Virus Latent Protein, LMP1, Suppresses LMP1-Expressing Tumor Growth and Metastasis in VivoLin et al., BMC Cancer (2016) - PMID: 28056887

Immune Monitoring to Predict and Prevent InfectionPalmer et al., US Patent 20,160,377,602, 2016 (2016) - PMID: na.

Predominance of Weakly Cytotoxic, T-betLowEomesNeg CD8+ T-Cells in Human Gastrointestinal Mucosa: Implications for HIV Infection.Kiniry et al., Mucosal Immunology (2016) - PMID: 27827375

Expression of DAI by an Oncolytic Vaccinia Virus Boosts the Immunogenicity of the Virus and Enhances Antitumor ImmunityHirvinen et al., Molecular Therapy (2016) - PMID: 27626058

αβ T Cell Receptor Germline CDR Regions Moderate Contact with MHC Ligands and Regulate Peptide Cross-ReactivityAttaf et al., Scientific Reports (2016) - PMID: 27775030

Mapping the Sequence Space of ZIKA and Related Viruses: High-Content Peptide Libraries for Immune Monitoringvon Hoegen et al., (2016) - PMID: n.a.

The Challenge of Complexity: Peptide Tools for the Development of ImmunotherapiesSchnatbaum et al., (2016) - PMID: n.a.

Circulating Functional T Cells Specific to HHV6 Antigens in Individuals With Chromosomally Integrated HHV-6 (ciHHV6)Barozzi et al., Clinical Microbiology and Infection (2016) - PMID: 27404369

Human Papillomavirus 16 (HPV16) and HPV52 E6-Specific Immunity in HIV-Infected Adults on Combination Antiretroviral TherapyLeng et al., HIV Medicine (2016) - PMID: 27649852

Immune Responses Elicited by the GEN-003 Candidate HSV-2 Therapeutic Vaccine in a Randomized Controlled Dose-Ranging Phase 1/2a TrialFlechtner et al., Vaccine (2016) - PMID: 27642130

Functional Diversity of CMV-Specific T-Cells is Maintained in Older People and Significantly Associated with Protein Specificity and Response SizeBajwa et al., The Journal of Infetious Diseases (2016) - PMID: 27521364

Self-Amplifying mRNA Vaccines Expressing Multiple Conserved Influenza Antigens Confer Protection against Homologous and Heterosubtypic Viral ChallengeMagini et al., PloS one (2016) - PMID: 27525409

Increased Frequency of BK Virus-Specific Polyfunctional CD8+ T Cells Predict Successful Control of BK Viremia After Kidney TransplantationSchaenman et al., Transplantation (2016) - PMID: 27391197

Protective Efficacy of Multiple Vaccine Platforms Against Zika Virus Challenge in Rhesus MonkeysAbbink et al., Science (2016) - PMID: 27492477

Distinct Metabolic Requirements of Exhausted and Functional Virus-Specific CD8 T Cells in the Same HostSchurich et al., Cell reports (2016) - PMID: 27452473

Complementary Effects of IL-15 and IFN-α Induce Immunity in HBV Transgenic MiceDi Scala et al., Journal of virology (2016) - PMID: 27440883

Composition and Dynamics of the Uterine NK Cell KIR Repertoire in Menstrual BloodIvarsson et al., Mucosal Immunol. (2016) - PMID: 27271316

Validation of an IFNγ/IL2 FluoroSpot Assay for Clinical Trial MonitoringKörber et al., J Transl Med. (2016) - PMID: 27297580

A Single Exercise Bout Enhances the Manufacture of Viral-Specific T-cells from Healthy Donors: Implications for Allogeneic Adoptive Transfer ImmunotherapySpielmann et al., Sci Rep (2016) - PMID: 27181409

Cellular Interferon Gamma and Granzyme B Responses to Cytomegalovirus-pp65 and Influenza N1 Are Positively Associated in ElderlyTheeten et al., Viral Immunology (2016) - PMID: 27002465

Reconstitution of Cytomegalovirus-Specific T-Cell Response in Allogeneic Hematopoietic Stem Cell Recipients: the Contribution of Six Frequently Recognized, Virus-Encoded ORFsNemeckova et al., Transpl Infect Dis. (2016) - PMID: 27061389

The VZV/IE63-Specific T Cell Response Prevents Herpes Zoster in Fingolimod-Treated PatientsMathias et al., Neurology (2016) - PMID: n.a.

Cytotoxic Polyfunctionality Maturation of Cytomegalovirus-pp65-specific CD4+ and CD8+ T-cell Responses in Older Adults Positively Correlates with Response SizeChiu et al., Sci Rep. (2016) - PMID: 26778409

Restoring Tissue-Like Functionality in Circulating CD8 T-Cells: Mechanistic Studies and Application in Immunomonitoring of Cancer PatientsWegner et al., Thesis for a doctoral degree at the Graduate School of Life Sciences, University Würzburg, Germany (2016) - PMID: n.a.

In Vitro Studies of the Impact of Maribavir on CMV-Specific Cellular Immune ResponsesStachel et al., J Clin Virol. (2015) - PMID: 26780109

Generation of Broadly-Specific, Virus-Immune Cells Targeting Multiple HIV Antigens For Prenventive and Therapeutic UseBollard et al., US Patent 20,150,359,876 (2015) - PMID: n.a.

Recombinant Particle Based Vaccines Against Human Cytomegalovirus InfectionWellnitz et al., US Patent 20,150,359,879 (2015) - PMID: n.a.

Induction Of Broad-Based Immunity and Protective Efficacy by Self-Amplifying mRNA Vaccines Encoding Influenza Virus HemagglutininBrazzoli et al., Journal of Virology (2015) - PMID: 26468547

Functionally Active HIV-Specific T Cells that Target gag and nef Can Be Expanded from Virus-Naive Donors and Target a Range of Viral Epitopes: Implications for a Cure Strategy after Allogeneic HSCTPatel et al., Biology of Blood and Marrow Transplantation (2015) - PMID: n.a.

Characteristics of Immune Memory 10–15 years After Primary Hepatitis B VaccinationHummel et al., Vaccine (2015) - PMID: n.a.

IL-12–Dependent Cytomegalovirus-Specific CD4+ T Cell Proliferation, T-bet Induction, and Effector Multifunction during Primary Infection Are Key Determinants for Early Immune ControlPopescu et al., J Immunol. (2015) - PMID: 26663780

Safety of Human Immunisation With a Live-attenuated Mycobacterium Tuberculosis Vaccine: a Randomised, Double-blind, Controlled Phase I TrialSpertini et al., The Lancet Respiratory Medicine (2015) - PMID: n.a

Luciferase mRNA Transfection of Antigen Presenting Cells Permits Sensitive Non-radioactive Measurement of Cellular and Humoral CytotoxicityOmokoko et al., Journal of Immunology Research (2015) - PMID: n.a.

A Novel Lipid Nanoparticle Adjuvant Significantly Enhances B Cell and T Cell Responses to Sub-unit Vaccine AntigensSwaminathan et al., Vaccine (2015) - PMID: 26555351

Peptide Libraries for the Comprehensive Coverage of the Tumor Mutanome for Immune Monitoring and Immuno Therapyvon Hoegen et al., Journal for ImmunoTherapy of Cancer (2015)- PMID: n.a.

Prognostic Impact of Circulating Her-2-reactive T-cells Producing Pro- and/or anti-inflammatory Cytokines in Elderly Breast Cancer PatientsBailur et al., J Immunother Cancer. (2015) - PMID: 26500775

Targeting of Nucleoprotein to Chemokine Receptors by DNA Vaccination Results in Increased CD8+-mediated Cross Protection Against InfluenzaBaranowska et al., Vaccine (2015) - PMID: 26387432

An Immunoinformatic Approach for Identification of Trypanosoma cruzi HLA-A2-Restricted CD8+ T cell EpitopesEickhoff et al., Hum Vaccin Immunother. (2015) - PMID: 26107442

Innate Immune Activity Correlates with CD4 T Cell-associated HIV-1 DNA Decline During Latency-Reversing Treatment with PanobinostatOlesen et al., Journal of Virology (2015) - PMID: 26223643

Chimpanzee Adenovirus– and MVA-Vectored Respiratory Syncytial Virus Vaccine is Safe and Immunogenic in AdultsGreen et al., Science Translational Medicine. (2015) - PMID: n.a

Efficacy of a Virus-Vectored Vaccine Against Human and Bovine Respiratory Syncytial Virus InfectionsTaylor et al., Science Translational Medicine. (2015) - PMID: n.a

Immune Reconstitution After Allogeneic Hematopoietic Stem Cell Transplantation and Association With Occurrence and Outcome of Invasive AspergillosisStuehler et al., The Journal of Infectious Disease. (2015) - PMID: 25748323

CD4+CD28null T Lymphocytes Resemble CD8+CD28null T Lymphocytes in Their Responses to IL-15 and IL-21 in HIV-infected PatientsEcheverría et al., J. Leukoc. Biol. (2015) - PMID: 26034206

Epstein-Barr Virus Reactivation Does Not Impact Total T-Cell Reconstitution But Is Associated With Decreased Functional T Cells after Stem Cell TransplantationPietersma et al., J Clin Cell Immunol (2015) - PMID: n.a

T Cells Specific for Different Latent and Lytic Viral Proteins Efficiently Control Epstein-Barr Virus–Transformed B CellsNowakowska et al., Cytotherapy (2015) - PMID: 26276009

Methods of Cell Culture for Adoptive Cell TherapyVera et al., US Patent 20,150,175,966, 2015 - PMID: n.a

High-Density Preculture of PBMCs Restores Defective Sensitivity of Circulating CD8 T Cells to Virus- and Tumor-derived AntigensWegner et al., Blood (2015) - PMID: 26024876

Metabolic Regulation of Hepatitis B Immunopathology by Myeloid-derived Suppressor CellsPallett et al., Nature Medicine (2015) - PMID: 25962123

ABO‐Desensitization Affects Cellular Immunity and Infection Control after Renal TransplantationSchachtner et al., Transplant International (2015) - PMID: 26033637

The Tuberculosis Vaccine H4: IC31 is Safe and Induces a Persistent Polyfunctional CD4 T cell Response in South African Adults: A Randomized Controlled TrialGeldenhuys et al., Vaccine (2015) - PMID: 26048780

Priming with a Simplified Intradermal HIV-1 DNA Vaccine Regimen followed by Boosting with Recombinant HIV-1 MVA Vaccine Is Safe and Immunogenic: A Phase Iia Randomized Clinical TrialMunseri et al., PloSOne (2015) - PMID: 25875843

Comparing Humoral and Cellular Immune Response Against HBV Vaccine in Kidney Transplant PatientsFriedrich et al., Am J Transplant. (2015) - PMID: 26137874

Guidelines For the Automated Evaluation of Elispot AssaysJanetzki et al., Nature Protocols (2015) - PMID: 26110715

Peripheral Blood–Derived Virus-Specific Memory Stem T Cells Mature to Functional Effector Memory Subsets with Self-Renewal PotencySchmueck-Henneresse, The Journal of Immunology (2015) - PMID: 25917088

A Comparative Phase 1 Clinical Trial to Identify Anti-infective Mechanisms of Vitamin D in People With HIV InfectionLachmann et al., AIDS (2015) - PMID: 25870995

HCV-Specific Lymphocyte Responses in Individuals with Positive Anti-HCV but Negative HCV-RNASili et al., Journal of Clinical Virology (2015) - PMID: n.a.

Safety and Immunogenicity of a Modified Vaccinia Ankara-based HIV-1 Vaccine (MVA-B) in HIV-1-Infected Patients Alone or in Combination with a Drug to Reactivate latent HIV-1Mothe et al., J Antimicrob Chemother. (2015) - PMID: 25724985

A Single Bout of Dynamic Exercise by Healthy Adults Enhances the Generation of Monocyte-Derived-Dendritic CellsLaVoy et al., Cellular Immunology (2015) - PMID: n.a.

Discordant Humoral and Cellular Immune Responses to Cytomegalovirus (CMV) in Glioblastoma Patients Whose Tumors are Positive for CMVRahbar et al., OncoImmunology (2015) - PMID: n.a.

Early Transduction Produces Highly Functional Chimeric Antigen Receptor-modified Virus-specific T-cells with Central Memory Markers: a Production Assistant for Cell Therapy (PACT) Translational ApplicationSun et al., J Immunother Cancer. (2015) - PMID: 25734008

Role of Naïve-Derived T Memory Stem Cells in T Cell Reconstitution Following Allogeneic TransplantationRoberto et al., Blood. (2015) - PMID: 25742699

Multispecific Aspergillus T Cells Selected by CD137 or CD154 Induce Protective Immune Responses Against the Most Relevant Mold InfectionsStuehler et al., The Journal of Infectious Disease (2015) - PMID: 25367298

Mycobacterium Tuberculosis-Specific and MHC Class I-Restricted CD8+ T-Cells Exhibit a Stem Cell Precursor-Like Phenotype in Patients with Active Pulmonary TuberculosisAxelsson-Robertson et al., Int J Infect Dis. (2015) - PMID: 25809750

The Loss of BKV-Specific Immunity From Pretransplantation to Posttransplantation Identifies Kidney Transplant Recipients at Increased Risk of BKV ReplicationSchachtner et al., Am J Transplant. (2015) - PMID: 25808077

Diagnostics ReagentsJones et al., US Patent 20,150,093,766 (2015) - PMID: n.a.

CMVpp65 Vaccine Enhances the Antitumor Efficacy of Adoptively Transferred CD19-Redirected CMV-Specific T CellsWang et al., Clin Cancer Res. (2015) - PMID: 25838392

Selection of Adenovirus-specific and Epstein-Barr virus–specific T Cells With Major Histocompatibility Class I Streptamers Under Good Manufacturing Practice (GMP)–Compliant ConditionsFreimüller et al., Cytotherapy (2015) - PMID: 25866178

Cutting Edge: Identification and Characterization of Human Intrahepatic CD49a+ NK CellsMarquardt et al., J Immunol. (2015) - PMID: 25672754

Potential role of CC Chemokine Receptor 6 (CCR6) in Prediction of Late‐onset CMV Infection Following Solid Organ TransplantCamargo et al., Clin Transplant. (2015) - PMID: 25690781

Polynucleotides for Treating Oncogenic Viral polypeptide Positive TumorsLee et al., US Patent 20,150,023,996, (2015) - PMID: n.a.

Functional Exhaustion limits CD4+ and CD8+ T Cell Responses to Congenital Cytomegalovirus InfectionHuygens et al., J Infect Dis. (2015) - PMID: 25657256

Early Exposure to Interleukin-21 Limits Rapidly Generated Anti–Epstein-Barr Virus T-cell Line DifferentiationOrio et al., Cytotherapy. (2015) - PMID: 25661862

STAT3 Signaling Contributes to the High Effector Activities of Interleukin-15-derived Dendritic CellsOkada et al., Immunol Cell Biol. (2015) - PMID: 25582338

Human Papillomavirus 16-Specific T-Cell Responses and Spontaneous Regression of Anal High-Grade Squamous Intraepithelial LesionsTong et al., J Infect Dis. (2015) - PMID: 25139018

Intracellular Cytokine Staining on PBMCs Using CyTOFTM Mass CytometryLin et al., bio-protocol.org - PMID: n.a.

The External Quality Assurance Oversight Laboratory (EQAPOL) Proficiency Program for IFN-gamma Enzyme-Linked ImmunoSpot (IFN-γ ELISpot) AssaySanchez et al., J Immunol Methods. (2014) - PMID: n.a.

Establishment and Maintenance of a PBMC Repository for Functional Cellular Studies in Support of Clinical Vaccine TrialsSambor et al., J Immunol Methods. (2014) - PMID: 24787274

CMV Specific Cytokine Release Assay in Whole Blood is Optimized by Combining Synthetic CMV Peptides and Toll Like Receptor AgonistsDammermann et al., Journal of Immunological Methods (2014) - PMID: n.a.

Naïve and Memory CD8 T Cell Pool Homeostasis in Advanced Aging: Impact of Age and of Antigen-specificRresponses to CytomegalovirusVescovini et al., Age (Dordr). (2014) - PMID: 24318918

Preformed Frequencies of Cytomegalovirus (CMV)–Specific Memory T and B Cells Identify Protected CMV-Sensitized Individuals Among Seronegative Kidney Transplant RecipientsLúcia et al., Clinical Infectious Diseases (2014) - PMID: 25048845

A Recombinant Modified Vaccinia Ankara Vaccine Encoding Epstein–Barr Virus (EBV) Target Antigens: A Phase I Trial in UK Patients with EBV-Positive CancerTaylor et al., Clin. Cancer Res. (2014) - PMID: 25124688

Human B Cells Produce Chemokine CXCL10 in the Presence of Mycobacterium Tuberculosis Specific T CellsHoff et al., Tuberculosis (2014) - PMID: n.a.

Expression of the Human Cytomegalovirus UL11 Glycoprotein in Viral Infection and Evaluation of its Effect on Virus-Specific CD8 T CellsGabaev et al., Journal of Virology (2014) - PMID: 25275132

HPV16-Specific T-Cell Responses and Spontaneous Regression of Anal High-Grade Squamous Intraepithelial LesionsTong et al., J Infect Dis. (2014) - PMID: 25139018

Immune Responses Againgst Mycobacterium Tuberculosis Targets Associated to Latent and Active Tuberculosis InfectionMontserrat Alvarez-Corrales, Published by Karolinska Institutet (2014) - PMID: n.a.

Preferential Infection of Human Ad5-Specific CD4 T Cells by HIV in Ad5 Naturally Exposed and Recombinant Ad5-HIV Vaccinated IndividualsHu et al., PNAS (2014) - PMID: 25197078

Diminished Humoral Responses Against and Reduced Gene Expression Levels of Human Endogenous Retrovirus-K (HERV-K) in PsoriasisGupta et al., Journal of Translational Medicine (2014) - PMID: 25224121

Gene Therapy for Rhesus Monkeys Heterozygous for LDL Receptor Deficiency by Balloon Catheter Hepatic Delivery of Helper-Dependent Adenoviral VectorOka et al., Gene Therapy (2014) - PMID: 25231173

Superior In Vitro Stimulation of Human CD8+ T-Cells by Whole Virus versus Split Virus Influenza VaccinesHalbroth et al., PLoS One (2014) - PMID: PLoS One (2014)

Activity of Broad-Spectrum T Cells as Treatment for AdV, EBV, CMV, BKV, and HHV6 Infections After HSCTPapadopoulou et al., Sci Transl Med. (2014) - PMID: 24964991

Development of an IFN-γ ELISpot Assay to Assess Varicella-Zoster Virus-specific Cell-mediated Immunity Following Umbilical Cord Blood TransplantationFourati et al., JoVE (2014) - PMID: 25046399

The Role of CD4+ T Cells in BKV-Specific T Cell ImmunityWeist et al., Med Microbiol Immunol. (2014) - PMID: 25052009

NetFCM: A Semi-Automated Web-Based Method for Flow Cytometry Data AnalysisFrederiksen et al., Cytometry A. (2014) - PMID: 25044796

T-Bet and Eomes Are Differentially Linked to the Exhausted Phenotype of CD8+ T Cells in HIV InfectionBuggert et al., PLoS Pathog. (2014) - PMID: 25032686

Specificities of Human CD4+ T Cell Responses to an Inactivated Flavivirus Vaccine and Infection: Correlation with Structure and Epitope PredictionSchwaiger et al., J Virol. (2014) - PMID: 24789782

Intralesional Treatment of Stage III Metastatic Melanoma Patients with L19-IL2 Results in Sustained Clinical and Systemic Immunological ResponsesWeide et al., American Association for Cancer Research (2014) - PMID: n.a

BK Polyomavirus‐Specific Cellular Immune Responses Are Age‐Dependent and Strongly Correlate With Phases of Virus ReplicationSchmidt et al., American Journal of Transplantation (2014) - PMID: 24726000

MART-1 Peptide Vaccination Plus IMP321 (LAG-3Ig fusion protein) in Patients Receiving Autologous PBMCs After Lymphodepletion: Results of a Phase I TrialRomano et al., Journal of Translational Medicine (2014) - PMID: 24726012

TLR2-Dependent Protection Against Pneumococcal Carriage by Immunization with Lipidated Pneumococcal ProteinsMoffitt et al., Infection and Immunol. (2014) - PMID: 24614661

An Enzyme-Linked Immunospot Assay for the Detection of Human Respiratory Syncytial Virus F-Specific IFNγ-producing T CellsPatton et al., Clin Vaccine Immunol. (2014) - PMID: 24574540

Influence of Frequent Infectious Exposures on General and Varicella-zoster Virus Specific Immune Responses in PediatriciansOgunjimi et al., Clin Vaccine Immunol. (2014) - PMID: 24429070

Deficient EBV-Specific B- and T-Cell Response in Patients with Chronic Fatigue SyndromeLoebl et al., PLOS ONE (2014) - PMID: 24454857

HIV Infection in Uncircumcised Men Is Associated With Altered CD8 T-cell Function But Normal CD4 T-cell Numbers in the ForeskinProdger et al., The Journal of Infectious Diseases (2014) - PMID: 24277744

Sustained Complete Responses in Patients With Lymphoma Receiving Autologous Cytotoxic T Lymphocytes Targeting Epstein-Barr Virus Latent Membrane ProteinsBollard et al., J Clin Oncol. (2013) - PMID: 24344220

Cytomegalovirus Vaccine Strain Towne-Derived Dense Bodies Induce Broad Cellular Immune Responses and Neutralizing Antibodies that Prevent Infection of Fibroblasts and Epithelial CellsCayatte et al., J. of Virology (2013) - PMID: 23926341

Mechanistic Insights Into the Impairment of Memory B Cells and Antibody Production in the ElderlyAberle et al., AGE (2013) - PMID: 22282053

Detection of Epstein-Barr Virus-Specific Memory CD4+ T Cells Using a Peptide-Based Cultured Enzyme-Linked Immunospot AssayCalarota et al., Immunology (2013) - PMID: 23560877

Nonreplicating Vaccines Can Protect African Green Monkeys from the Memphis 37 Strain of Respiratory Syncytial VirusEyles et al., Journal of Infectious Diseases (2013) - PMID: 23596321

Overnight Resting of PBMC Changes Functional Signatures of Antigen Specific T- Cell Responses: Impact for Immune Monitoring within Clinical TrialsKutscher et al., PLoS One (2013) - PMID: 24146841

Inflammatory Activation and Recovering BKV-specific Immunity Correlate with Self-Limited BKV Replication after Renal TransplantationSchachtner et al., Transplant International (2013) - PMID: 24279642

Adoptive Immunotherapy with Antigen-Specific T Cells During Extracorporeal Membrane Oxygenation (ECMO) for Adenovirus-Related Respiratory Failure in a Child Given Haploidentical Stem Cell TransplantatioDi Nardo et al., Pediatric Blood & Cancer (2013) - PMID: 24039155

Rapid Generation of EBV-Specific Cytotoxic T Lymphocytes Resistant to Calcineurin Inhibitors for Adoptive ImmunotherapyRicciardelli et al., American Journal of Transplantation (2013) - PMID: 24266973

The Immunogenicity of Virus-Derived 2A Sequences in Immunocompetent IndividualsArber et al., Gene Therapy (2013) - PMID: 23698740

Adoptive T-Cell Transfer and Chemotherapy in the First-Line Treatment of Metastatic and/or Locally Recurrent Nasopharyngeal CarcinomaChia et al., Molecular Therapy (2013) - PMID: 24297049

Combination of Epstein-Barr Virus Nuclear Antigen 1, 3 and Lytic Antigen BZLF1 Peptide Pools Allows Fast and Efficient Stimulation of Epstein-Barr Virus-Specific T Cells for Adoptive ImmunotherapyWang et al., Cytotherapy (2013) - PMID: 24094498

A Novel Cytomegalovirus-Induced Regulatory-Type T-Cell Subset Increases in Size During Older Life and Links Virus-Specific Immunity to Vascular PathologyTerrazzini et al., The Journal of Infectious Disease (2013) - PMID: 24203779

Putting Polyphosphates to the Test: Evidence Against Platelet-Induced Activation of Factor XIIFaxälv et al., Blood (2013) - PMID: 23896408

Short-Term In-Vitro Expansion Improves Monitoring and Allows Affordable Generation of Virus-Specific T-Cells against Several Viruses for a Broad Clinical ApplicationGeyeregger et al., PLOS ONE (2013) - PMID: 23630567

Adoptive Transfer of Epstein-Barr Virus (EBV) Nuclear Antigen 1–Specific T Cells As Treatment for EBV Reactivation and Lymphoproliferative Disorders After Allogeneic Stem-Cell TransplantationIcheva et al., JCO (2013) - PMID: 23169501

Human Papillomavirus Type 16 E6/E7-Specific Cytotoxic T Lymphocytes for Adoptive Immunotherapy of HPV-Associated MalignanciesRamos et al., Journal of Immunotherapy (2013) - PMID: 23211628

Cytomegalovirus-Specific CD4 and CD8 T Cell Responses in Infants and ChildrenLidehäll et al., Scandinavian Journal of Immunology (2013) - PMID: 23216075

The Effects of Age and Latent Cytomegalovirus Infection on the Redeployment of CD8+ T Cell Subsets in Response to Acute Exercise in HumansSpielmann et al., Brain, Behavior, and Immunity (2013) - PMID: 23684819

The Third Signal Cytokine IL-12 Rescues the Anti-Viral Function of Exhausted HBV-Specific CD8 T CellsSchurich et al., PLOS Pathogens (2013) - PMID: 23516358

Antibody Quality and Protection from Lethal Ebola Virus Challenge in Nonhuman Primates Immunized with Rabies Virus Based Bivalent VaccineBlaney et al., PLOS Pathogens (2013) - PMID: 23737747

Donor-Derived CMV-Specific T Cells Reduce The Requirement For CMV-Directed Pharmacotherapy After Allogeneic Stem Cell TransplantationBlyth et al., Blood. (2013) - PMID: 23435462

Antigen-Reactive T Cell Enrichment for Direct, High-Resolution Analysis of the Human Naive and Memory Th Cell RepertoireBacher et al., J. Immunol. (2013) - PMID: 23479226

An Adjuvanted Herpes Simplex Virus 2 Subunit Vaccine Elicits a T Cell Response in Mice and Is an Effective Therapeutic Vaccine in Guinea PigsSkoberne et al., J. Virol. (2013) - PMID: 23365421

Distinct Gene-Expression Profiles Associated With the Susceptibility of Pathogen-Specific CD4 T Cells to HIV-1 InfectionHu et al., Blood. (2013) - PMID: 23258923

IL-7– and IL-15–Mediated TCR Sensitization Enables T Cell Responses to Self-AntigensDeshpande et al., J. Immunol. (2013) - PMID: 23325887

Up-Regulation of a Death Receptor Renders Antiviral T Cells Susceptible to NK Cell–Mediated DeletionPeppa et al., J. Exp. Med. (2012) - PMID: 23254287

Reconstitution of Protective Immune Responses against Cytomegalovirus and Varicella Zoster Virus Does Not Require Disease Development in Pediatric Recipients of Umbilical Cord Blood TransplantationMerindol et al., J. Immunol. (2012) - PMID: 23034171

Antiviral T Cell Response Triggers Cytomegalovirus Hepatitis in MiceLivingston-Rosanoff et al., J. Virol. (2012) - PMID: 22993151

Full-Length HIV-1 Immunogens Induce Greater Magnitude and Comparable Breadth of T Lymphocyte Responses to Conserved HIV-1 Regions Compared with Conserved-Region-Only HIV-1 Immunogens in Rhesus MonkeysStephenson et al., J. Virol. (2012) - PMID: 22896617

Polyclonal Mucosa-Associated Invariant T Cells Have Unique Innate Functions in Bacterial InfectionChua et al., Infect. Immun. (2012) - PMID: 22778103

Differential Patterns of Large Tumor Antigen-Specific Immune Responsiveness in Patients with BK Polyomavirus-Positive Prostate Cancer or Benign Prostatic HyperplasiaSais et al., J. Virol. (2012) - PMID: 22647697

Single-Cell Level Response of HIV-Specific and Cytomegalovirus-Specific CD4 T Cells Correlate With Viral Control in Chronic HIV-1 Subtype A InfectionEller et al., J Acquir Immune Defic Syndr (2012) - PMID: 22580564

A Novel Th Cell Epitope of Candida albicans Mediates Protection from Fungal InfectionBär et al., J. Immunol. (2012) - PMID: 22529294

Three Sensitive Assays Do Not Provide Evidence for Circulating HuD-specific T Cells in the Blood of Patients with Paraneoplastic Neurological Syndromes with Anti-Hu Antibodiesde Jongste et al., Neuro Oncology. (2012) - PMID: 22591661

Performance of the QuantiFERON-Cytomegalovirus (CMV) Assay for Detection and Estimation of the Magnitude and Functionality of the CMV-Specific Gamma Interferon-Producing CD8+ T-Cell Response in Allogeneic Stem Cell Transplant RecipientsClari et al., Clin Vaccine Immunol May (2012) - PMID: 22379065

The Thai Phase III Trial (RV144) Vaccine Regimen Induces T Cell Responses That Preferentially Target Epitopes within the V2 Region of HIV-1 Envelopede Souza et al., J. Immunol. (2012) - PMID: 22529301

Preferential Expansion of Human Virus-Specific Multifunctional Central Memory T Cells by Partial Targeting of the IL-2 Receptor Signaling Pathway: The Key Role of CD4+ T CellsSchmueck et al., J. Immunol. (2012) - PMID: 22516956

T-Cell Therapy for EBV-Associated Nasopharyngeal Carcinoma: Preparative Lymphodepleting Chemotherapy Does not Improve Clinical ResultsSecondino et al., Ann. Onc. (2012) - PMID: 21586688

A Whole Blood Monokine-Based Reporter Assay Provides a Sensitive and Robust Measurement of the Antigen-Specific T Cell ResponseChakera et al., Journal of Translational Medicine (2011) - PMID: 21871084

Live and Inactivated Influenza Vaccines Induce Similar Humoral Responses, but Only Live Vaccines Induce Diverse T-Cell Responses in Young ChildrenHoft et al., The Journal of Infectious Disease (2011) - PMID: 21846636

Rebound of Residual Plasma Viremia After Initial Decrease Following Addition of Intravenous Immunoglobulin to Effective Antiretroviral Treatment of HIVMellberg et al., AIDS Research and Therapy (2011) - PMID: 21708049

A Phase II Study Evaluating the Safety and Efficacy of an Adenovirus-LMP1-LMP2 Transduced Dendritic Cell Vaccine in Patients with Advanced Metastatic Nasopharyngeal CarcinomaChia et al., Ann. Onc. (2011) - PMID: 21821548

Polyomavirus BK Large T-Antigen Derived Peptide Elicits a HLA-DR Promiscuous and Polyfunctional CD4+ T-cell ResponseRamaswami et al., Clin. Vaccine Immunol (2011) - PMID: 21367979

Expansion of T Cells Targeting Multiple Antigens of Cytomegalovirus, Epstein – Barr Virus and Adenovirus to Provide Broad Antiviral Specificity After Stem Cell TransplantationHanley et al., Cytotherapy (2011) - PMID: 21539497

Adoptive Transfer of EBV-Specific T Cells Results in Sustained Clinical Responses in Patients With Locoregional Nasopharyngeal CarcinomaLouis et al., J Immunother (2010) - PMID: 20948438

Effective and Long-Term Control of EBV PTLD After Transfer of Peptide-Selected T CellsMoosmann et al., Blood (2010) - PMID: 20103780

Accelerated Production of Antigen-Specific T-Cells for Pre-Clinical and Clinical Applications Using Gas-permeable Rapid Expansion Cultureware (G-Rex)Vera et al., J Immunother. (2010) - PMID: 20445351

Derivation of Human T Lymphocytes From Cord Blood and Peripheral Blood with Antiviral and Antileukemic Specificity from a Single Culture as Protection Against Infection and Relapse after Stem Cell TransplantationMicklethwaite et al., Blood (2010) - PMID: 20110422

Absence of Systemic Immune Response to Adenovectors After Intraocular Administration to Children With RetinoblastomaIldefonso et al., Molecular Therapy (2010) - PMID: 20606647

Nucleofection of DCs to Generate Multivirusspecific T Cells for Prevention or Treatment of Viral Infections in the Immunocompromised HostGerdemann et al., Molecular Therapy (2009) - PMID: 19584818

Cytotoxic T Lymphocyte Therapy with Donor T Cells Prevents and Treats Adenovirus and Epstein-Barr Virus Infections after Haploidentical and Matched Unrelated Stem Cell TransplantationLeen et al., Blood (2009) - PMID: 19700662

Tuberculosis Subunit Vaccination Provides Long-Term Protective Immunity Characterized by Multifunctional CD4 Memory T CellsLindenstrom et al., J. Immunol (2009) - PMID: 19494330

Enhancing the In Vivo Expansion of Adoptively Transferred EBV-Specific CTL with Lymphodepleting CD45 Monoclonal Antibodies in NPC PatientsLouis et al., Blood (2009) - PMID: 18971421

Mesenchymal Stem Cells Exert Differential Effects on Alloantigen and Virus-Specific T-cell ResponsesKarlsson et al., Blood (2008) - PMID: 18445691

Prospective Monitoring of Polyomavirus BK Replication and Impact of Pre-Emptive Intervention in Pediatric Kidney RecipientsGinevri et al., American Journal of Transplantation (2007) - PMID: 17908275

Contact-Activated Monocytes: Efficient Antigen Presenting Cells for the Stimulation of Antigen-specific T cellsLeen et al., J Immunother (2007) - PMID: 17198088